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ABSTRACT 
 Stromal cell-derived factor-1α (SDF-1α) and its key receptor, CXCR4 are 
ubiquitously expressed in systems across the body (e.g. liver, skin, lung, etc.). This 
signaling axis regulates a myriad of physiological processes that range from maintaining 
of organ homeostasis in adults to, chemotaxis of stem/progenitor and immune cell types 
after injury. Given its potential role as a therapeutic target for diverse applications, 
surprisingly little is known about how SDF-1α mediated signaling propagates through 
native tissues. This limitation ultimately constrains rational design of interventional 
biomaterials that aim to target the SDF-1α/CXCR4 signaling axis. One application of 
particular interest is traumatic brain injury (TBI) for which, there are currently no 
means of targeting the underlying biochemical pathology to improve prognosis.  
 Growing evidence suggests a relationship between SDF-1α/CXCR4 signaling and 
endogenous neural progenitor/stem cells (NPSC)-mediated regeneration after neural 
injury. Long-term modulation of the SDF-1α/CXCR4 signaling axis is thus hypothesized 
as a possible avenue for harnessing and amplifying endogenous regenerative 
mechanisms after TBI. In order to understand how the SDF-1α/CXCR4 signaling can be 
modulated in vivo, we first developed and characterized a sustained protein delivery 
platform in vitro. We were the first, to our knowledge, to demonstrate that protein 
release profiles from poly(D,L,-lactic-co-glycolic) acid (PLGA) particles can be tuned 
independent of particle fabrication parameters via centrifugal fractioning. This process 
of physically separating the particles altered the average diameter of a particle 
population, which is in turn was correlated to critical release characteristics. Secondly, 
we demonstrated sustained release of SDF-1α from PLGA/fibrin composites (particles 
embedded in fibrin) with tunable burst release as a function of fibrin concentration. 
Finally, we contrasted the spatiotemporal localization of endogenous SDF-1α and CXCR4 
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expression in response to either bolus or sustained release of exogenous SDF-1α. 
Sustained release of exogenous SDF-1α induced spatially diffuse endogenous SDF-
1/CXCR4 expression relative to bolus SDF-1 administration; however, the observed 
effects were transient in both cases, persisting only to a maximum of 3 days post 
injection. These studies will inform future systematic evaluations of strategies that 
exploit SDF-1α/CXCR4 signaling for diverse applications. 
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PREFACE 
 The work represented in this dissertation document has been previously 
published in the form of two review articles (Chapters 1 & 2, J. Polym. Sci. Part B, 2012 
[1], & Biomarker Insights, 2015 [2]) and two original research articles (Chapters 3, 4, J. 
Biomed. Mater. Res. A, 2015 [3], & J. Mater. Chem., 2015 [4]). These published works 
have been expanded upon and adapted for use in this dissertation document.  
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CHAPTER 1 
INTRODUCTION 
 The general public has a grasp of the overall function of stem cells during the 
developmental stages of life; they are self-renewing units that divide to create new and 
specialized cells. However, the reality that the majority of tissues in adult humans also 
contain populations of stem cells has yet to disseminate as widely. In fact, the idea of a 
stem cell originated in the 19th century as a hypothesis for how an adult can self-renew 
short-lived cells (i.e. skin, blood etc.) over an entire lifetime [5]. Although most of the 
stem cells found in adults are restricted to only certain cell types or lineages (i.e. they do 
not have the potency of an embryonic stem cell), they do have the capacity to: 1) self-
renew perpetually and, 2) give rise to new, and fully differentiated cell types. One of their 
main functions in healthy adults is to, generate fully differentiated cells at the rate at 
which they are lost (i.e. maintain homeostasis).  
 Another complementary hypothesis beginning to gain favor is that stem cells in 
adults are also meant to help cope with environmental stresses. For example, injury or 
disease in adults activates/amplifies similar cellular signaling that guide stem cell-
mediated tissue generation during development. The ligand, stromal cell-derived factor-1 
(SDF-1) and its key receptor, CXCR4 has garnered significant attention due to its 
correlation with stem cell-mediated regenerative processes in the injured liver, muscle, 
heart, bone and central nervous system (CNS) [6]. This chapter will first introduce the 
SDF-1/CXCR4 cellular signaling cascade and its importance to tissue engineering as a 
whole. The work presented is in the context of traumatic brain injury (TBI), and thus the 
motivation and its pathophysiology will be discussed. Finally, this section will end with a 
discussion on bioengineering approaches for protein delivery centered on SDF-1/CXCR4 
signaling in the CNS.  
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1.1 The Stromal Cell-Derived Factor-1α (SDF-1α) and CXCR4 Signaling Axis 
1.1.1 Stromal Cell-Derived Factor-1: The Molecule and its Receptors 
 Stromal cell-derived factor-1 (SDF-1) is a chemoattractant cytokine (chemokine) 
with a molecular weight of ~8-14kDa and an isoelectric point of pH ~9.6 [4]. 
Chemokines are generally classified in four groups (CXC, CC, C, and CX3C); SDF-1 
belongs to the CXC family and is also commonly known as CXCL12. Six splice variants of 
the SDF-1 gene have been identified. The two most studied isoforms are: 1) SDF-1α, an 
89 amino acid protein that is the predominant isoform found in most tissues and, 2) 
SDF-1β, which has four additional amino acids at the C-terminus [7]. The remaining four 
isoforms have 1, 30, 31 and 51 amino acid extensions at the C-terminus and are known 
as, SDF-1ε, SDF-1γ, SDF-1δ, and SDF-1φ, respectively [8]. All alternate splice variants 
are expected to be functional and are differentially expressed throughout the body. The 
functional significance for the diversity in splicing variants and how their expression is 
regulated is unclear. SDF-1α has a short plasma half-life of 25mins and the extensions at 
the C-terminus may putatively provide protection from proteases (e.g. carboxypeptidase 
N) [9], [10].  However, quantitative analysis contrasting bioactivity and stability between 
all known SDF-1 isoforms is currently unavailable [9]. SDF-1α is the most common 
variant of SDF-1/CXCL12 used to conduct studies in literature thus far. 
 Chemokines interact with receptors of the G-protein-coupled seven-span 
transmembrane receptor (GPCR) superfamily. The first receptor discovered to interact 
with SDF-1 is the CXC receptor 4 (CXCR4). Similar to other GPCR receptors, SDF-
1α/CXCR4 binding initiates mitogen-activated protein kinase (MAPK) signaling through 
the Akt and ERK1/2, and IP3 pathways that regulate intracellular calcium concentrations 
as well as, cell survival, proliferation, activation and chemotaxis [11]–[14]. In addition, β-
arrestin pathway can also be activated to internalize the SDF-1α/CXCR4 complex. 
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Mechanisms controlling CXCR4 internalization and subsequent recycling is not clear, 
but may provide means for tuning sensitivity to extracellular SDF-1α [11], [13]. Recent 
studies have shed light on a second receptor, CXC receptor 7 (CXCR7) that is also 
implicated in regulating SDF-1α-mediated signaling [15]. CXCR7 is an atypical 
chemokine receptor thought to be incapable of transducing any intracellular signaling 
characteristic of chemokine receptor activation (i.e. intracellular calcium mobilization, 
MAPK signaling etc.) [16]. Thus, some reports characterize CXCR7 as a decoy receptor 
with the role of sequestering SDF-1 [17], [18]. Conflicting reports propose mechanisms 
for CXCR7-mediated intracellular signal transduction and regulation through 
heterodimerization with CXCR4 among other mechanisms [19], [20]. Others studies 
indicate CXCR7-mediated signaling may be more important for regulating angiogenesis 
in tumor development [17], [21]. The full extent of interactions and interplay between 
SDF-1α, CXCR4 and CXCR7 remains to be determined. However, the SDF-1α/CXCR4 
signaling axis, and the directed migration of CXCR4+ cells are more widely 
characterized. 
 1.1.2 Function and Regulation in Healthy Tissues 
 Morphogenesis requires migration of precursor cells to reach developing organs 
where they undergo proliferation and differentiation. SDF-1/CXCR4 signaling is 
instrumental in orchestrating the migratory patterns and organization of 
stem/progenitor cells during development. CXCR4 is expressed in several types of 
precursor cells that include embryonic pluripotent stem cells as well as, multipotent 
stem cells (e.g. neural, skeletal lineages etc.) [6]. In addition, to CXCR4 expression, these 
precursor cells also have the capacity to migrate down SDF-1 gradients [22]. Genetic 
knockout of either SDF-1 or CXCR4 genes in mice is lethal, causing embryonic death in 
utero due to anomalous organ structures [23]. Multiple studies have shown that critical 
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developmental processes such as, hematopoiesis, organogenesis (cardiac, cerebellar, 
renal, gastro- intestinal tract etc.), angiogenesis, B-cell development and others are at 
least partly guided by the SDF-1/CXCR4 signaling axis [6], [22]–[25]. 
 After development, populations of (multi- or uni-potent) stems cells in healthy 
adults are found ubiquitously in organs throughout the body in specialized 
microenvironments termed, niches [26], [27]. Stem cell activity in their niches is highly 
regulated and varies depending on the type/function of tissue. An important role of SDF-
1α/CXCR4 signaling in adults is to direct these populations of stem cells towards 
maintaining organ homeostasis. For example, the turnover rate for blood cells is high 
relative to cells in other types of tissues. As such, hematopoietic stem cells in adult bone 
marrow continuously produce new cells at a complimentary rate [23]. Similarly, 
proliferation and cellular turnover is also high in the epidermis and the intestinal 
epithelium compared to the central nervous system (CNS) or liver, where the stem cells 
are retained in a more quiescent state [26]. The SDF-1/CXCR4 signaling axis plays 
important roles specific to the modulation of endogenous stem cells.  
1.1.3 Function and Regulation during Pathology 
 The SDF-1/CXCR4 signaling axis has a hand in perpetuating a number of 
pathological states. Migration of cancer stem cells (CSC) is important in tumor growth 
and metastasis. Populations of CSCs are documented for leukemia, and tumors in the 
brain, breast, lungs, prostate and others [6], [28]–[32]. CSCs in most (if not all) of these 
cases are CXCR4+ and respond to a SDF-1 gradients [6]. As a result, several studies 
indicate chemoattraction of CSCs towards organs with relatively high SDF-1 levels [28], 
[29], [32]. For example, CXCR4+ CSCs from, breast and prostate cancers selectively 
metastasize to the bones and/or lymph nodes, presumably in an SDF-1 gradient-
dependent manner [29], [32]. Aberrant expression of SDF-1/CXCR4 is also associated to 
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several CNS disorders such as dementia, multiple sclerosis, among others [14]. SDF-
1/CXCR4 signaling controls homing of systemic immune cells and may also be 
implicated in autoimmune disorders such as adhesion and chemotaxis of autoimmune 
lymphocytes [33], [34]. Furthermore, CXCR4 is one of the primary receptors that 
mediate infectivity of human immunodeficiency virus-1 in leukocytes [35].  
 On the other hand, SDF-1/CXCR4 signaling plays a key role in managing the 
endogenous repair response after injury. Secretion of SDF-1 has been detected by 
stromal and endothelial cells of the brain, heart, liver, kidney, skeletal muscle and others 
[22]. In fact, evidence suggests that proliferative, migratory and differentiation cues are 
upregulated to mobilize endogenous stem cells after injury across diverse systems of the 
body. For example overexpression of SDF-1 is detected in damaged tissues that include 
the brain [36], skin [37], heart [38], liver [39], bone [40], and damage due to 
chemotherapy [22], [41]. Local overexpression of SDF-1 acts as a homing beacon for 
local and systemic CXCR4+ stem cells that migrate specifically to areas of injury. CD34+ 
stem cells in the peripheral circulatory system migrate across the basal lamina of the 
endothelium after local activation of cell-adhesive integrins to follow a SDF-1 source in 
the parenchyma of injured tissue, such as the brain [21], [42], [43]. Once at the site of 
injury, stem/progenitor cells promote regeneration, not only by providing trophic 
support, but also through differentiation and integration to replace lost tissues [2]. This 
form of stem cell homing through SDF-1/CXCR4 signaling is observed for diverse tissues 
throughout the body and is thus considered a promising therapeutic target for 
regeneration. The adult CNS has its own stem cell niche(s) and there are ongoing efforts 
to regulate its function in the context of various pathological conditions such as stroke, 
Alzheimer’s disease, cancer, etc. Our interest in SDF-1/CXCR4 signaling within the CNS 
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specifically relates to the activity of endogenous neural progenitor/stem cells after 
traumatic brain injury (TBI).   
1.2. Epidemiology of Traumatic Brain Injury (TBI) 
 Approximately 5.3 million individuals are affected by traumatic brain injury 
(TBI) annually, within the US alone [44], [45]. Among them, 43% of TBI survivors report 
having sustained and/or progressive disabilities one year after injury [46]. TBI is also 
correlated to the development of other disorders such as chronic traumatic 
encephalopathy, dementia, depression, epilepsy and Alzheimer’s disease [47], [48]. 
Moreover, the incidence of TBI has been on the rise in recent years largely attributed to 
military conflicts as well as increasing popularity of football, soccer and other forms of 
contact-sports [45]. As such, TBI accounts for an estimated $76.5 billion strain on U.S. 
healthcare and economy each year [2]. TBI represents a substantial public health 
concern that has garnered public attention in recent years. 
1.3. Pathophysiology of Traumatic Brain Injury  
 Trauma to the brain is classified in two categories based on etiology and the 
resulting biochemical sequelae. Acute injury refers to concussions, mild-to-moderate 
TBI, as well as catastrophic, or severe TBI brain injury that may lead to death [49]. 
Chronic injuries on the other hand, is characterized by sustained and progressive 
neurodegenerative disorders such as chronic traumatic encephalopathy (CTE) [50]. 
Acute injuries also increase the risk factor of developing chronic disorders. For example, 
CTE is correlated to repeated concussions and/or mild TBIs prevalent in contact sports 
such as boxing, ice hockey etc. [50]. The outcome of mild-to-severe TBI is further 
dependent on two disparate phases of injury. The first phase known as, the primary 
injury, is defined as damage to neural tissues and its vasculature caused directly by a 
mechanical insult. The magnitude, location and directionality of forces (blast, linear 
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and/or rotational forces) dictate the effects of the primary damage (i.e. focal, diffuse, 
severity etc.).  Primary injuries cause contusion(s), laceration(s), intracranial 
hemorrhaging, ischemia and neuronal death (by necrosis) [2]. The primary injury 
subsequently sets off a complex series of biochemical signaling cascades that propagate 
at the cellular and sub-cellular scales resulting in secondary injury. This prolonged phase 
of the injury is due to imbalances in the metabolic and ionic homeostasis, as well as, 
inhibitory autocrine and paracrine signaling between CNS and systemic cell types [51], 
[52]. Secondary injury is characterized by breakage of the blood-brain-barrier (BBB), 
chronic inflammation and upregulation of apoptotic/necrotic pathways. The sustained 
effects of secondary injury may persist for weeks causing progressive functional and 
cognitive impairments.  
1.3.1. TBI Injury Progression 
 A period of hyperglycolysis begins immediately after the primary insult around 
the injury site that lasts for 0.5 - 4hours in animal models [53], [54]. Unregulated release 
of excitatory neurotransmitters, such as glutamate and aspartate, is thought to be a 
contributing factor [55]. Glutamate-mediated generation of sustained action potentials 
(leading to excitotoxicity) greatly increases the metabolic rate of the affected area(s) 
through the activity of ion pumps attempting to maintain adequate ion concentration 
gradients [51], [55], [56]. Non-excitable cells such as astrocytes also contribute to post-
TBI hyperglycolysis. In addition to providing structural and metabolic support, 
astrocytes aid neurons by maintaining ionic homeostasis and regulating 
neurotransmitter concentrations [57]. Increased rates of neuronal firing after injury 
causes a massive efflux of ions (such as potassium) into the brain extracellular matrix 
(ECM) which in-turn activates astrocytic ion (and glutamate) pumps [57]. This action 
increases the overall metabolic demand to unsustainable levels in the injured tissue since 
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damage to the vasculature leads to inadequate rates of both, nutrient and waste product 
exchange [51]. As a result, cellular ATP stores eventually deplete and increases the 
concentrations of ADP, AMP, lactic acid and eventually uric acid as well as reactive 
oxygen species [58]. Glutamate also causes overstimulation of calcium ion channels, 
increasing intracellular calcium concentration [56]. High calcium levels combined with 
reactive oxygen species formation begins catabolic metabolism processes that include 
increased (plasma and mitochondrial) membrane permeability, DNA structural changes 
and eventually, activation of apoptotic signaling [51].  
 At the cellular level, the primary injury initiates neuroinflammation comprised of 
complex cellular interactions and phenotypic changes. Moreover, infiltrating systemic 
leukocytes and macrophages (mobilized by upregulation of adhesion molecules and 
chemokines) may also participate in the inflammation after TBI [59]. A number of 
proinflammatory factors are upregulated within minutes after injury and may also 
include proteases, lipid peroxidases and vasoconstrictors that further aggravates the 
injury microenvironment [2], [51]. Aberrant neurotransmitter and soluble signaling 
factor concentrations activates microglia, the resident immune cells and phagocyte of the 
CNS [52]. Activated microglia act to insulate the injury area form healthy tissue through: 
1) directed movement of its processes and 2) migrating to the injury site, if necessary 
[47]. In the acute phase of injury, activated microglia, release more glutamate as well as, 
pro- and anti-inflammatory cytokines [51], [52]. Disruptions in metabolic and ionic 
homeostasis plays a role in cellular influx of Ca2+, Na+ and K+ ions, where Ca2+ influx 
is thought to be initiate astrogliosis (adopting the reactive astrocyte phenotype) after 
brain injury [51], [60], [61]. In addition, rises in intracellular Ca2+ also induces 
astrocytes to release vasoconstrictors (endothelin-1), matrix metallopeptidase 9 
(degrades ECM) and more glutamate [62]. 
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 At the tissue level, neural injury immediately leads to a disparity in cerebral 
blood flow and metabolic need due to either hypo- (causing ischemia) or hyperperfusion 
(increasing intracranial pressure). Focal or global ischemia (hypoperfusion) may occur 
after TBI where the ischemic brain volume is directly associated with overall 
neurological outcome [51]. Osmotic imbalance caused by breakdown of autoregulatory 
processes often leads to edema formation (and increases intracranial pressure) after TBI. 
Disruption of blood vessels activates the coagulation cascade leading to deposition of 
intravascular thrombi in the pericontusional brain tissue. This post-traumatic 
coagulation process occludes venules and, possibly arterioles leading to further 
reductions in local blood flow [63]. Neural injury invariably leads to the breakage of the 
BBB where TBI severity is correlated to the extent of BBB breakage [64]. Additionally, 
catabolic/proteolytic processes, infiltration of systemic cells, neuroinflammation, 
oxidative stress and other factors have shown to exacerbate BBB permeability post-
injury [65]. The cumulative inhibitory signaling and auto-regulatory failure may lead to 
further long term neuronal loss and as a result, degradation of motor and cognitive 
functions, well after the primary injury. 
1.3.2. Duality of Signaling Molecule and Cellular Function 
 An important consideration for the injury microenvironment is the duality in 
function of the majority of signaling mediators after injury. For example, interleukin 
factor 1 (IL-1) is a pro-inflammatory factor synthesized mainly by activated microglia in 
the CNS. IL-1 acts synergistically with tumor necrosis factor alpha (TNF-α), another pro-
inflammatory factor, to orchestrate the immune response and exacerbate glutamate 
mediated neuronal excitotoxicity [66], [67]. Interestingly, IL-1 interaction with 
astrocytes also shows an upregulation of the neurotrophic factor, nerve growth factor 
(NGF), a well-known neuroprotective agent [68]. In fact, this type of dual-role behavior 
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is observed for several cytokines [52], including the anti-inflammatory signal, IL-6, 
which on one hand, inhibits TNF-α and stimulates angiogenesis, but on the other, 
upregulates chemotactic signaling and adhesion molecule production that promotes 
recruitment of monocytes from the systemic circulation [69], [70]. Another example is 
SDF-1α, a potent chemotactic agent important in regulating the endogenous 
regeneration after injury, but it also has been correlated to a tumorigenic potential 
(mobilization of cancer stem cells) and neuropathic pain [71].  
 The same duality in activity that some cytokines seem to exhibit is also true for 
certain CNS cell types. For example, although astrocytes play a pivotal role during the 
acute injury phase (metabolic support, production of neurotrophic factors), they are also 
heavily involved in the process of glial scar formation later on; a process that is thought 
to inhibit neural regeneration [72]. As mentioned earlier, microglia are involved in 
excitotoxicity of neurons, release of pro-inflammatory cytokines and other inhibitory 
functions. At the same time, they have also been shown to release neurotrophic factors, 
degrade cellular debris/non-functional proteins from dead or dying cells and modulate 
neural plasticity by helping to incorporate new neurons into existing networks [73], [74]. 
This functional duality of cellular/molecular mediators in the injury microenvironment 
may be one reason why current clinical treatments for TBI do not yet address the 
underlying biochemical pathology. 
1.3.3. Current Treatment Practices & Clinical Trials 
 Lack of effective treatments for TBI is considered one of the greatest unmet needs 
in modern medicine [75]. Immediately after the patient’s arrival to a hospital due to a 
moderate to severe TBI, the first priority is rapid patient resuscitation (if needed) and 
stabilization. Subsequently, standard protocols involve only management of symptoms 
rather than treatment of underlying pathologies. The intracranial pressure and cerebral 
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blood flow is monitored and if necessary, a craniotomy may be performed to address 
increased intracranial pressure [76]. Additionally, there are no reliable means of 
preventing worsening of symptoms, only addressing them as they manifest. For example, 
anticonvulsant treatments are administered if the patient develops post-traumatic 
seizures [76]. For the sub-acute and chronic phases on injury, treatment is usually 
limited to behavior/cognitive therapy that include therapeutic exercise, psychological 
interventions, sleep management etc. [76]. No phase III clinical trials for neuroprotective 
agents have shown a significant benefit after TBI [75].  
1.4. The Role of Neural Progenitor/Stem Cells (NPSC) after TBI 
 Until a few decades ago, neurogenesis in adults from endogenous sources was 
thought to be unlikely, if not impossible. In the 1960’s, several studies began to challenge 
that notion, notably with the discovery of immature neurons in the dentate gyrus of the 
hippocampus [77], [78]. Today, the community has established a degree of 
understanding about the maintenance, migration, differentiation and integration of 
neuronal precursors in the CNS during normal and pathological conditions. 
1.4.1. The Neurogenic Niche in the Healthy Adult Brain 
 The neurogenic niches for neural progenitor/stem cells (NPSC) are located near 
the subgranular zone (SGZ) in the dentate gyrus of the hippocampus and the 
subventricular zone (SVZ) of the lateral ventricles. Their normal functions include 
continuous generation of neuroblasts in the SVZ that migrate along the rostral migratory 
stream reaching the olfactory bulb (OB). Once at the OB, they are capable of 
differentiating into interneurons and integrating into existing circuitry (Figure 1A) [2], 
[79]. In rodents, this process is thought to give rise to approximately 30,000 immature 
neurons in the olfactory bulb, per day [79]. Neuronal precursors produced in the SGZ, on 
the other hand, is associated with hippocampal neuroplasticity. Altogether, the activity of 
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NPSCs in adult brains is indispensable for learning, memory tasks and maintenance of 
CNS homeostasis.  
1.4.2. NPSC Response to Neural Injury 
 After neural injury (e.g. stroke and TBI), proliferation rates in NPSC niches 
increases significantly, particularly in the SVZ. The niche physically increases in size to 
accommodate a greater number of cells [2], [80]. Furthermore, migrating NPSCs deviate 
from the RMS and undergo vasophilic migration to selectively accumulate forming 
ectopic niches at the site of injury (Figure 1B) [2], [36], [81]. NPSCs subsequently 
participate in modulating the signaling milieu in the injury site by secreting neurotrophic 
and anti-inflammatory factors; presumably in an effort for neuroprotection and 
regeneration. Moreover, NPSC-mediated neurogenesis in adults is not restricted simply 
to the SGZ, SVZ, olfactory bulb and the hippocampus. After injury to the CNS, NPSC-
derived immature neurons have been detected in otherwise non-neurogenic areas of the 
brain such as the cortex and the striatum [4]. NPSCs also assist in preserving synaptic 
connectivity in the injury area [82]. As such, ablation of endogenous NPSC populations 
before induction of neural injury significantly exacerbates its cognitive impairments 
[83]. Moreover, neurogenesis in the cortex have been reported up to 4 months post-
stroke in a rodent model; indicating a sustained regenerative effort from endogenous 
NPSCs after injury [84]. However, it is also important to note that even with such a 
complex endogenous repair response after injury, its effectiveness is quite low especially 
when compared to other tissues in the body (e.g. liver).  
1.4.3. Soluble Signaling Factors that Regulate NPSC Activity after Neural Injury 
 SDF-1α expression increases within the injury penumbra within 24 hours after 
TBI and persists to approximately 3 days before reaching basal levels [81], [85]. Both in 
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vitro and in vivo data indicate that local increases in SDF-1α is mediated by endothelial 
cells, perivascular astrocytes, as well as reactive astrocytes in the peri-lesion site after 
neural injury [36], [85], [86]. Unpublished data from our lab largely agrees with 
literature where SDF-1α within the injury penumbra peak at 1-3 days post injury (DPI) 
and returns back to basal between 7-14 days following a rodent controlled cortical impact 
(CCI). Similar to pattern of SDF-1α overexpression in the injured cortex, NPSC 
migratory response peaks at 1-3 DPI and decreases dramatically, although not 
completely, by two weeks post injury [87]. SDF-1α also has a role in increasing NPSC 
proliferation in vitro, however this relationship is not as well defined in the context of 
TBI [2].  
 A number of other critical signaling factors play an important role on NPSC 
recruitment after neural injury [2]. Vascular endothelial growth factor (VEGF) may act 
directly and indirectly to induce NPSC migration and proliferation [2]. Epidermal 
growth factor (EGF) and fibroblast growth factor (FGF) are other both implicated in the 
increased proliferation of NPSCs in their niches after injury [2], [88]. Brain-derived 
neurotrophic factor (BDNF), on the other hand plays a more critical role in controlling 
NPSC differentiation and survival [89]. Overexpression of the above signaling mediators 
that mobilize NPSCs after injury are usually short-lived (especially for SDF-1α, VEGF, 
FGF & BDNF) [2]. Their concentrations reach basal levels only days post injury, 
coinciding with the transient migratory response of NPSCs after neural injury [2]. In 
addition to modulating NPSC activity, these factors directly and indirectly act on a 
myriad of other cells and signaling cascades [2]. Thus, from an engineering point of view, 
carefully modulating the bioavailability of these proteins may be a means for achieving a 
therapeutic effect after neural injury [2]. 
1.5. Strategies for Modulating the Injury Microenvironment 
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 The injury site is inundated with a myriad of soluble and immobilized signaling 
factors that have complex interplay and cross-talk. We are beginning to understand how 
some of the intracellular signaling overlap of different signaling mediators may be of 
therapeutic benefit [12]. In addition to events in the molecular scale, the diversity in cell-
types that participate in regulating the injury microenvironment adds to its intricacy. 
More importantly, many of the critical parameters in the injury microenvironment (pH, 
ionic stress, expression of signaling mediators & enzymes, cell types & their phenotype, 
BBB leakage, etc.) are dependent on the type of primary injury and are dynamic 
spatially, temporally. Despite this complexity, tuning the injury microenvironment may 
still be possible to bias the overall signaling milieu towards neuroprotection and 
neuro/angiogenesis. This goal may be achieved through delivery of proteins [2], 
agonist/antagonists [90]–[93], soluble receptors [94], [95], exogenous stem cells and 
amplifying the endogenous NPSC recruitment. The following sections will specifically 
explore how proteins may be used to modulate the injury microenvironment.  
1.5.1. Stem Cell Transplants 
 Cellular therapy has gained considerable attention as potential means for treating 
diverse disorders in the CNS [96]–[99]. A wide range of studies in the CNS have tested 
various cell types, mesenchymal stem cells (MSCs) [100] & NSCs [101]; gene-modified 
stem cells [102], [103]; stem cells encapsulated in hydrogels [104]; as well as, how, where 
and when they are delivered [101], [105]–[109]. Several authors have reported functional 
improvements using these therapeutic systems employed in animal models [108], [110]–
[112]. However, positive results have been mostly elusive in human trials [96], [113]. 
Cumulative results of stem cell therapy in animal models indicate that survival, retention 
and neuronal differentiation of implanted stem cell is <5% [2]. Such a low rate of 
implant survival indicates that functional improvements seen in animal models cannot 
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solely be attributed to implant-derived generation and integration new neurons. Instead, 
implants of exogenous stem cells are correlated to an increase in the concentration of 
neurotrophic factors (e.g. SDF-1α, BDNF, VEGF, FGF and others) and anti-inflammatory 
cytokines available to injury microenvironment [114]–[116]. Stem cell implants can 
therefore be considered to also function as a depot for releasing complex cocktails of 
proteins that tune the biochemical milieu of the injury microenvironment. Additionally, 
stem cell encapsulation in hydrogels, genetic modified and “priming” could not only 
produce more resilient phenotypes, but may also better bolster their capacity to provide 
trophic support [2], [104].  
 Although exogenous stem cell transplants hold great therapeutic potential, their 
transition to the clinic may be limited by scarcity of cell sources, high costs and possible 
regulatory hurdles [117]. Modulation of the endogenous populations of stem cells is thus 
an important alternative, which has yet to receive the same degree of attention as the 
field of exogenous cell implants. Moreover, cellular signaling that regulates injury 
response of endogenous stem cells (e.g. the SDF-1α/CXCR4 signaling axis) has overlap 
across diverse systems of the body. The following sections will discuss protein delivery in 
the CNS with a focus on proteins that regulate NPSC activity after injury. 
1.5.2. Protein Delivery: Challenges in the CNS 
 A quick look at the pathophysiology of TBI indicates that increased bioavailability 
of specific signaling mediators may be used to regulate processes or biochemical 
cascades of interest to affect injury outcome. To that extent, a variety of different types of 
therapeutic approaches have been proposed which include protein (neurotrophic 
factors)[118]–[124],[125],[126], agonist/antagonist[90]–[93], soluble receptor 
delivery[94], [95] using several forms of carrier systems[94], [125], [127]. As discussed in 
the earlier sections, the cellular mechanisms for endogenous neurotrophic support and 
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neurogenesis exist even in non-neurogenic areas of the brain, like the cortical tissues, 
after TBI or stoke. An important (yet, often overlooked) avenue for tissue engineering is 
to modulate/amplify this innate capacity of NPSCs for: 1) directed, long-distance 
migration, 2) for their ability to provide trophic support in the injury area and, 3) even 
neuronal differentiation as well as integration. Protein delivery to modulate NPSC 
activity will need to first address some CNS-specific challenges. 
1.5.2.1. Developing & Testing Biomaterials for the CNS 
 Recapitulating the complexity of the injury microenvironment in vitro to test the 
efficacy of biomaterials is exceedingly difficult.  For example, if natural, biodegradable 
hydrogel-based systems are implanted, the effect of proteolytic enzymes that maybe 
overexpressed is difficult to model. Degradation of non-bioinert components and protein 
deposition may affect the mechanical properties of an implant. Materials will also be 
exposed to aberrant ionic concentrations and pH levels, which is especially relevant in 
biodegradable, poly-ester-based systems. In addition, specific and non-specific 
adsorption of cargo with components in the injury micro-environment may add to 
discrepancies between expected in vitro and effective in vivo release profiles [128]. 
Activated immune cells also present a special problem for nanoparticle-based systems. 
Initiation of phago/endocytosis cascades in the presence of nanometer scale particles is 
common and may also contribute to attenuating the protein concentration gradients for 
protein release applications [14].  
1.5.2.2. The Blood-Brain-Barrier (BBB) 
 In addition to difficulties of modeling the injury environment in the CNS, another 
formidable challenge is access to the CNS. The BBB is made of specialized brain 
microvessel endothelial cells (BMEC), pericytes and astrocytes that maintains exquisite 
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control over molecular and cellular transport between blood and the CNS [2]. BMECs are 
characterized by the presence of an unusually low concentration of pinocytic vesicles at 
the luminal side and tight junctions between adjacent cells that prevent cell migration 
and virtually eliminate passive and paracellular transport of molecules through simple 
diffusion into the CNS [64]. On the parenchymal side, glial cells that make intimate 
contact with the BBB where normal function is regulated by paracrine/autocrine 
signaling of perivascular astrocytes and microglia [130]. These morphological and 
functional properties of the BBB represent a challenge for engineers looking to deliver 
therapeutic agents (especially lipid-insoluble molecules) to the CNS.  
1.5.2.3. Routes of Delivery to the CNS 
 Intravenous (i.v.) or subcutaneous administration of proteins are subjected to a 
number of factors such as rapid clearance/degradation from the serum, and limited to no 
penetration of the BBB, especially of large proteins/peptides [131]. As a result, one study 
reports brain uptake of FGF was only about ~0.01% of the total injected dose [132]. 
Brain injury (i.e. TBI or stroke) may cause the BBB to be permeable for up to 3 days after 
injury [64]. This disrupting represents a potential time window where therapeutic agents 
(proteins and carriers such as, nanoparticles) can accumulate at relatively high 
concentrations in the brain interstitium. However, a global biodistribution of injected 
agent may increase risks of unwanted side effects. Intravenous injections may be 
applicable in cases where BBB is being “tricked” into letting the therapeutic agents pass 
into the CNS by mimicking properties of molecules that have the ability to traverse the 
BBB [133]. 
 Intranasal delivery has garnered attention due to its ability to bypass the BBB in a 
non-invasive fashion and its patient-friendly nature. The exact mechanism(s) for its 
action is yet to be elucidated but one hypothesis states that following adsorption to the 
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nasal mucosa, the nerves from the nasal passages facilitate in transport to the olfactory 
bulb, spinal cord and cerebrospinal fluid [120]. Intranasal delivery appears to cause 
greater accumulation of drug in the olfactory bulb immediately after infusion, followed 
by diffusion-based transport to the rest of the brain [120], [134]. It is important to note 
that this can result in uneven and possibly sub-therapeutic concentrations of drug in 
certain areas of interest. 
 Intrathecal injections are made directly in the subarachnoid space of the spinal 
cord and thus bypass the BBB to access the CSF. Intrathecal route can be used in 
conjunction with a slow infusion device for sustained release of therapeutic agents. 
However, intrathecal injections can be risky; improper needle or catheter placement can 
cause serious patient complications [135].  
 Intracerebroventricular (i.c.v.) and intracortical injections are infusions directly 
in the ventricles or in the cortical interstitium, respectively. These forms of injections 
require surgical intervention and thus have associated risks. Infusion through the i.c.v. 
route means that the protein/drug has to pass the ependymal lining and in combination 
with slow diffusion, causes high drug accumulation at the ventricle lining relative to 
deeper in the brain parenchyma. The CSF in the ventricles are constantly renewed (every 
~5 hrs in humans) and thus investigators will also need to consider the rate at which 
infused drugs will be cleared back out into the systemic circulation [135]. Intracortical 
injections allow for a significantly higher dose of drug/protein to be delivered to the 
cortex. However, in addition to risks associated with its invasive nature, diffusion is the 
rate limiting means of transport and thus injected agents usually only penetrate in the 
order of  millimeters (or less) from its source [136].  
1.5.3. Protein Delivery: Rational Design Criterion 
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 Although, administration of proteins has long been assessed experimentally for 
their potential of neuroprotective and regenerative effects for a wide variety of CNS 
conditions, no commercially available solutions have survived the scrutiny of clinical 
trials. All modes bypassing the BBB subject proteins to one or more factors such as 1) 
rapid clearance from the serum/CSF, 2) degradation and/or loss of activity due to 
protein half-life and 3) limited to no penetration of the BBB, especially of large 
proteins/peptides [2]. Moreover, for cases where the BBB is bypassed, diffusion limited 
penetration of drug/protein into the brain parenchyma poses another significant hurdle 
[136]. As a result, maintaining an appropriate local concentration of a therapeutic agent 
over a desired time window is especially challenging in the CNS. 
1.5.3.1 Spatio-temporal Presentation of Proteins Affect the Biological Response  
 Precise control over the concentration and localization of biomolecules is a pre-
requisite for much of cellular signaling at multiple size and time scales. In addition to 
immobilized components such as ECM and lipid rafts in plasma membranes [137], 
evidence for organization also exists for freely soluble components such as 
transmembrane ion gradients. and spatial gradients of proteins involved in transduction 
of intracellular signaling [138] as well as extracellular concentration gradients of 
chemotactic signals [71], [81]. While the amount/concentration of exogenous protein 
delivered is a critical design parameter, the spatio-temporal bioavailability is thus also 
important (Figure 1.2). For example, intraventricular bolus injection of EGF after the 
fluid percussion injury model in rodents induces preferential differentiation of NPSCs 
towards an astroglial cell fate in the dentate gyrus and the SVZ [139]. However, epi-
cortical sustained release of EGF after cortical ischemia led to a higher number of NPSCs 
differentiating into neurons in the SVZ [140]. In this case, data suggests controlled 
release of EGF is likely to be a more efficacious means of promoting neurogenesis. 
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Another study found that sustained release of BDNF in vitro affects the terminal 
phenotypes of differentiated NPSCs relative to daily BDNF supplementation in soluble 
form [141].  
 In other cases, sustained release of drug does not always produce a greater 
benefit compared to one of multiple bolus injections. Nutropin Depot® (Genentech, San 
Diego CA, and Alkermes, Cambridge, MA) was designed for controlled release of human 
growth hormone (HGH) to improve compliance in patients with growth hormone 
deficiency. Sustained release failed to show a significant improvement in therapeutic 
outcome relative to daily dosage [142]. Another example indicates that the 
antidepressant-like effects of BDNF when delivered over a short period of time (2 days) 
could not be replicated when BDNF was delivered over 10 days [143]. Additionally, 
receptor desensitization/downregulation due to over and/or continuous stimulation is 
another well-known phenomenon that may be applicable in controlled release devices 
[144], [145]. These are some indications that delayed or pulsed release may be more 
beneficial to achieve a therapeutic benefit for specific applications. One important 
example is how pulsatile release of insulin performs significantly better compared to 
sustained release at a constant concentration [146]. Thus, the same bioactive factor, 
when presented differently (spatially and/or temporally) may be expected to change the 
overall biochemical response. However, there is a paucity of studies looking to 
systematically contrast how protein release profiles affects the biological outcome. 
Development of a range of protein release platforms to have better spatial and/or 
temporal control may therefore be instrumental in understanding how a system of 
interest may be modulated efficiently.  
1.5.3.2. Delivery of Multiple Growth Factors 
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 Co-delivery and/or orchestrated delivery of proteins is an idea that is gaining 
traction in the field due to its potential for inducing an enhanced or even synergistic 
effect on functional recovery. Kojima and Tater report that co-delivery of EGF and FGF-2 
intrathecally after SCI increased proliferation rates, migration of ependymal cells (may 
give rise to NPSCs) and spare white matter; whereas delivery of either of the two factors 
alone did not elicit the same response [147], [148]. Additional studies looking at 
neurotrophin co-delivery indicate feasibility in the CNS after injury [127], [149], [150]. 
Delayed release, or orchestrated release of proteins is another strategy of interest in 
applications where spatio-temporal presentation of proteins is critical for a desired 
outcome. For example, a sequential release profile of two, or more proteins that mimic 
biological patterns is hypothesized to stimulate angiogenesis [151]. In other cases, 
delayed or pulsed protein release could be especially useful for systems susceptible to 
protein desensitization [144], [145]. 
1.5.4. Protein Delivery: Protein Carriers for the CNS in Literature 
 Withstanding the above limitations, delivery of proteins has been proposed for 
and tested in pre-clinical CNS injury/disease models. The cumulative data from such 
studies indicate that exogenous delivery of bioactive components can 1) elicit desired 
biological responses in the CNS and 2) produce positive therapeutic outcomes as 
measured by histological and/or behavioral outcomes. The sub-sections below will 
summarize broad categories of biomaterials-based approaches to deliver bioactive 
proteins in the CNS. 
1.5.4.1. Hydrogels 
 Hydrogels are hydrated polymeric constructs that maintain viscoelastic 
properties from physical and/or chemical crosslinks. Due to their high water content, 
22 
 
possibility for modification/functionalization (especially in synthetic polymers) and 
inherent similarities to biological tissues, hydrogels are an attractive class of materials 
for biological applications in drug/protein delivery. Due to its hydrated nature, water 
soluble biomolecules can simply be mixed into the gel matrix and delivered locally, often 
in injectable form [1]. A simple mixing process to encapsulate proteins in an aqueous 
environment is more likely to preserve protein structure and thus, its bioactivity. 
Subsequent release of cargo occurs through four major mechanisms: 1) diffusion-
mediated 2) swelling-mediated 3) chemical reaction-mediated and 4) a combination of 
mechanisms 1, 2 and/or 3 [152]. Additionally, cargo-carrier interactions may 
significantly affect release rates [4], [153]. In general, diffusion is commonly the rate-
limiting mechanism controlling release of encapsulated cargo from hydrogels. Thus, 
achieving sustained release of hydrophilic proteins (e.g. chemokines like SDF-1α) for 
extended periods of time (weeks) is unlikely using hydrogel-based systems [4]. Systems 
that have been investigated for protein delivery to the brain include fibrin (VEGF), 
alginate (VEGF), agarose (BDNF), collagen (VEGF, BDNF, FGF), poly(ethylene glycol)-
derivatives (BDNF), 2-hydroxyethyl methacrylate (FGF), chitosan (FGF), 
hyaluronan/methylcellulose blends (EGF) and others [4], [140], [154]–[161]. Cumulative 
results for these devices indicate increased bioavailability of cargo through controlled 
release [154], control over NPSC phenotype in vitro & in vivo [140][155] as well as, 
increased NPSC proliferation and migration [156]. 
1.5.4.2. Polyester-Based Biomaterials 
 Polyester-based biodegradable materials hold the capacity for sustained protein 
release over longer periods of time relative to hydrogels. Poly(D,L,-lactic-co-glycolic) 
acid (PLGA) and polylactic acid (PLA) are two examples that are FDA-approved for use 
in humans. Protein release form PLGA-based systems is mediated by a combination of 
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cargo diffusion and bulk degradation of the PLGA carrier [129]. However, release is 
generally thought to be limited by polymer degradation rate and thus extended release 
(over months) has been widely reported [3], [4], [162]. Release profiles can be tuned by 
modulating properties of the polymer (e.g. molecular weight, copolymer ratio, end group 
functionalization), as well as characteristics of the carrier (e.g. size, morphology etc.) 
[129], [163]. Examples in literature include, achieving sustained release of FGF using 
PLGA nanoparticles [158]. Fon et. al. NPSCs along the migratory pathway originating 
from the SVZ to the OB (via the RMS) can be redirected towards poly ε-caprolactone 
(PCL) implants loaded with a short BDNF-mimetic ligand [164]. In a similar study, the 
orientation of the BDNF-loaded PCL nano-fibers affects NPSC proliferation and 
differentiation, indicating both physical and chemical cues can be used to modulate 
NPSC behavior [159]. Sustained release of BDNF from PLGA-poly(L-lysine)-
polyethylene glycol (PEG) microspheres have also been proposed [165]. Composite 
materials that include both hydrogels and polyester-based devices are beginning to be 
explored to exploit/combine characteristics of both systems. For example, loaded into 
FGF-loaded PLGA nanoparticles dispersed within the HAMC to achieve a long-term, 
linear release rate with low burst release [166].  
1.5.5. Exogenous SDF-1α Delivery in the CNS 
 Intracortical delivery of SDF-1α after lateral fluid percussion model of TBI 
showed some efficacy in inducing CD34+ stem cell–mediated angiogenesis [167]. SDF-1 
treated groups exhibited increased local expression of CXCR4, which colocalized with 
CD34+ cells in the injury area. SDF-1 increased microvessel density in treated animals 
and behavioral tests corroborated histological findings with improvements in functional 
outcome [167]. Moreover, blocking SDF-1α/CXCr4 signaling through injection of a 
soluble antibody significantly decreased microvessel density and aggravated functional 
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outcome, suggesting an important link between CD34+ stem cell mediated angiogenesis 
and the SDF-1α/CXCR4 signaling axis. In a different study, intracortical administration 
of soluble SDF-1α, 24h post TBI led to a lower degree of BBB disruption, decrease in 
brain edema, lower expression of pro-inflammatory cytokines and attenuated neuronal 
apoptosis in the area surrounding the injury [168]. Other studies show SDF-1α infusion 
into the lesion site after spinal cord injury (SCI) promotes axonal sprouting that is 
correlated to plasticity-associated functional recovery [71], [169].  
 A growing body of evidence supports the therapeutic efficacy of prolonged SDF-
1α delivery for various applications such as wound healing[170], [171], [172], skeletal 
regeneration [173], [174] and myocardial infractions [175], [176], [177], [178]. These 
studies demonstrate the viability of recruiting progenitor cells through exogenous 
infusion of SDF-1α. However, there is a lack of studies that specifically elucidate the in-
vivo effects and feasibility of local, bolus/controlled release of SDF-1α in the context of 
TBI/stroke. Sustained release of exogenous SDF-1α to attract/amplify the number of 
endogenous NPSCs appearing at the injury site after TBI or an ischemic insult in-vivo 
has yet to be demonstrated. A number of devices have been proposed that hopes to 
achieve controlled release of SDF-1α over different time periods that include SDF-1α 
loaded star PEG-heparin hydrogels [179], PLGA microparticles [180], chitosan-
tripolyphosphate based nanoparticles [181], poly(lactide ethylene oxide furmate) 
hydrogels [182], as well as a composite gelatin/dextran and poly(N-
isopropylacrylamide)-based stimuli sensitive hydrogel [183]. The above systems have 
been characterized in-vitro and seems to maintain bioactivity of encapsulated SDF-1α to 
various degrees. However, no such device for the sustained release of SDF-1α has been 
evaluated in-vivo after TBI or stroke to our knowledge.  
1.6. Objective and Specific Aims 
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 The innate recruitment of NPSCs from their neurogenic niches to the site of 
neural injury (e.g. after stroke or TBI) is correlated to a local increase in SDF-1α 
concentration and CXCR4 expression acutely in the injury penumbra [36], [81]. 
However, local SDF-1α concentrations subsequently reach baseline sub-acutely, and is 
presumably a key factor contributing to a significant decrease observed in NPSC homing 
[81], [87]. Increased bioavailability of SDF-1α from exogenous sources is thus expected 
to amplify and sustain NPSC recruitment [4], [36], [81].  
 Despite a large preponderance of evidence that suggests a link between SDF-
1α/CXCR4 signaling and NPSC recruitment, previous studies conducted using various 
rodent models of has only focused on immune-modulation, neuroprotection and 
angiogenesis in response to bolus treatments of SDF-1α [21], [168], [184]. SDF-1α 
release devices has been proposed for various applications, but they lack tunability of 
release profiles and have inherently short (diffusion-limited) release periods of 7-14 days 
[170], [171], [173], [178]. Thus, many of these previous designs (based on alginate, 
collagen, gelatin, star PEG–heparin etc.) do not significantly extend bioavailability of 
SDF-1α past what is observed for endogenous SDF-1α in the injury penumbra. Since 
NPSC activity in the injury penumbra has been observed, months after neural injury, 
long-term release of SDF-1α is believed to have therapeutic merit [84]. To achieve 
sustained release of SDF-1α for longer periods, others have employed biodegradable 
polyesters to achieve sustained release for 40-70days [172], [180], [185]. However, the 
priority of these studies was to explore the feasibility of encapsulating SDF-1α rather 
than modulation of the release profile and in vivo testing. Our first goal was to develop 
tunable controlled release devices capable of sustained release of bioactive SDF-1α on the 
order months. 
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 Our second goal aims to address gaps in our understanding of the in vivo 
spatiotemporal interplay between endogenous SDF-1α/CXCR4 expression in response to 
exogenous SDF-1α. As such, rational design of biomaterials that mediate predictable and 
long-term manipulation of endogenous SDF-1α/CXCR4 signaling axis is not yet feasible. 
Our approach is to contrast sustained release of SDF-1α with the biochemical effects of 
bolus injections. We utilized CXCR4-EGFP transgenic mice to probe the effects of 
fluorophore-tagged, exogenous SDF-1α [186]. This animal model allows us to distinguish 
spatiotemporal localization of endogenous SDF-1α/CXCR4 as opposed to exogenous 
SDF-1α. The long-term goal of the proposed research is to harness the regenerative 
potential of endogenous NPSCs with clinically translational protein-based therapies that 
reduce motor and cognitive deficits after TBI. Our central hypothesis is that local 
spatiotemporal bioavailability of exogenous SDF-1α mediates differential endogenous 
SDF-1α expression and temporal autoregulation of CXCR4. Our rationale for these 
studies is to inform and enable future systematic evaluations of strategies that exploit 
SDF-1α/CXCR4 signaling to amplify and/or sustain the innate NPSC migration after 
injury. The results may confirm or challenge the overall inclination of the community to 
focus heavily on devices that mediate sustained release of proteins rather than other 
types of release profiles, for example one that exhibits “on/off” release characteristics. 
The experimental approach included the following specific aims: 
1.6.1. Specific Aim 1: Validate platform for controlled release of proteins 
with tunable release profiles. 
  Tuning the size distribution of a population of poly(D,L,-lactic-co-glycolic acid) 
(PLGA) nanoparticles (NP) alters the overall protein release profile. 
1.6.2. Specific Aim 2: Explore composite release systems to modulate 
sustained release of bioactive SDF-1α.  
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 PLGA NPs are hypothesized to sustain release of bioactive SDF-1α. Additionally, 
the positive net surface charge & heparin-binding properties of SDF-1α can be exploited 
through non-covalent SDF-1α/hydrogel interactions to further tune the release profile 
from SDF-1α-loaded PLGA NPs. 
1.6.3. Specific Aim 3: Determine spatiotemporal expression of endogenous 
SDF-1/CXCR4 after administration of exogenous SDF-1 in the intact mouse 
cortex.  
 Hypothesis 3a: Endogenous SDF-1/CXCR4 expression will increase acutely after 
exposure to both bolus and controlled release of exogenous SDF-1. Hypothesis 3b: Bolus 
administration leads to transient overexpression of SDF-1/CXCR4. Hypothesis 3c: 
Sustained release of exogenous SDF-1α leads to downregulation of CXCR4 expression 
overtime. 
 Specific aim (SA) 1 explored various means of achieving a tunable sustained 
protein release platform. PLGA-based particulate devices were the most promising due 
to its 1) versatility, and 2) ability to sustain protein release over the period of months. 
During this process we developed novel means of tuning protein release profiles from 
PLGA particles without altering their fabrication parameters. SA2 validated and 
characterized SDF-1α encapsulation and release from PLGA nanoparticles. In addition, 
we reported novel protein-affinity based tuning SDF-1α burst release from fibrin/PLGA 
nanoparticle composites. Finally, SA3 aimed to compare the two most common forms of 
protein delivery, bolus and sustained release and contrasted how spatiotemporal 
presentation of exogenous SDF-1α affected the endogenous SDF-1α/CXCR4 signaling 
axis.  
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1.7. Figures 
 
Figure 1.1: NPSC migratory behavior in the (A) normal and (B) injured brain. In normal 
conditions, NPSCs originating from the subventricular zone (SVZ) migrate using the 
rostral migratory stream (RMS) to reach the olfactory bulb where they participate in 
neural turnover. After TBI, migrating NPSCs deviate off of the RMS to selectively 
accumulate at the site of injury where they exert trophic support and hold the capacity 
for neuronal differentiation.  
 
Figure 1.2: The route of delivery to the central nervous system plays a critical role in 
determining the spatial and temporal distribution of infused agents. (A) Demonstrates 
conventional means of bypassing the blood–brain barrier, which includes the 
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intracortical, intracerebroventricular, and intrathecal routes. Each route of delivery has 
its own strengths and weaknesses, and thus outcome of therapy depends heavily on 
proper selection of the means of administering the therapeutic agent/construct. 
Intrathecal injections are made directly in the subarachnoid space of the spinal cord, 
whereas intracerebroventricular and intracortical injections refer to infusion of drugs 
directly into the ventricles or into the cortical interstitium, respectively. Efficiency of 
drug accumulation in the CNS is very low, even in the cases where the blood–brain 
barrier is bypassed. This is especially a challenge for applications where high drug 
concentrations are required in a specific portion of the brain. (B) Bolus injections of a 
therapeutic have rather transient effects with minimal time in the therapeutic threshold 
window; however, (idealized) controlled release of bioactive molecules may achieve 
sustained biochemical effects throughout the therapeutic time window.  
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CHAPTER 2 
TAILORING RELEASE PROFILES OF PROTEIN-LOADED SUB-MICRON PLGA 
PARTICLES USING CENTRIFUGAL FRACTIONING 
2.1. Introduction 
The popularity of the FDA-approved biodegradable polymer poly(D,L-lactic-co-
glycolic acid) (PLGA) for drug delivery applications is not surprising due to the 
versatility of PLGA. Specifically, PLGA can encapsulate both water-soluble and insoluble 
molecules, facilitates tunable cargo release profiles, holds the potential for direct 
injection into target tissues, and consists of metabolizable degradation products [1], 
[187]–[190]. Moreover, PLGA matrices maintain prolonged, localized bioavailability and 
may aid in protecting the encapsulated cargo from degradation, a critical parameter for 
protein-based cargo [187], [191], [192]. Sub-micron PLGA particles are of particular 
interest due to the potential engineering opportunities for deeper tissue infiltration, 
improved cellular internalization and ability to circulate and accumulate in target tissues 
[187], [189], [193]–[195]. However, utility of PLGA particle systems can be compromised 
by undesirable release profiles, such as the characteristic large burst phase, which is 
followed by the desired steady state release profile. Therefore, mechanisms to tailor and 
refine specific aspects of the release profile are highly desirable for drug delivery 
applications.  
One of the most common fabrication methods for PLGA particles is emulsion 
with solvent evaporation. Here, the fabrication parameters largely dictate the resulting 
particle morphological characteristics and thus play a critical role in determining cargo 
loading capacity and the resulting release profile (see reviews [163], [196], [197]). 
Previous studies have evaluated the influence of the fabrication parameters on the cargo 
loading and release from PLGA particles to provide general formulation trends on 
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obtaining broad release profile characteristics [188], [198], [199]. However, seemingly 
simple changes in the PLGA particle formulation may ultimately lead to a loss of 
desirable attribute(s) [197], [200]. For example, altering the polymer concentration in 
the organic phase reportedly affects both particle size and porosity, which in turn 
influences the encapsulation efficiency and initial burst release[201], [202]. In another 
example, varying the emulsifier concentration significantly affects particle size, zeta 
potential and encapsulation efficiency [202], [203]. Each particle formulation must 
therefore be thoroughly characterized to verify the final release properties. As a result, 
fine-tuning release profiles based solely on altering formulation parameters may prove 
substantially challenging and highly laborious.  
Here, we describe modulation of sub-micron PLGA particle s properties via a 
centrifugal fractioning technique to refine the initial poly-dispersed population to refine 
particle sub-populations. The significance of this approach is that we have applied it to 
study encapsulation and release of protein for particles of varying diameter that were 
otherwise prepared identically. We hypothesized that the average particle diameter 
would directly affect protein loading and subsequent release characteristics. This post-
fabrication approach is the first, to our knowledge, to directly evaluate the effect of PLGA 
particle size on critical release parameters while holding all fabrication parameters 
constant. Bovine serum albumin (BSA)-loaded sub-micron particles were fabricated with 
identical formulation conditions and then subjected to centrifugal fractioning. We 
observed particle size-dependent effects on the encapsulation efficiency, burst release, 
subsequent protein release rate and total release period. The results from this report 
significantly impact future PLGA micro/nanoparticle studies that may employ this 
technique as an additional tool to tune and achieve a desired release profile without 
altering baseline fabrication formulation parameters. 
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2.2. Experimental Methods 
2.2.1. PLGA Particle Formulation  
 Sub-micron PLGA particles were synthesized via a W/O/W emulsion technique 
adopted from a method further described by McCall et al [204]. In short, the organic 
phase comprised of 100 mg/mL PLGA (PLGA; 50:50 ester-terminated; inherent 
viscosity = 0.55-0.75dL/g; Lactel, Birmingham, AL, USA) in ethyl acetate (Alfa Aesar; 
Ward Hill, MA, USA). The first emulsion was generated by vortexing the organic phase 
with a phosphate-buffered saline (PBS) solution containing 20mg/mL BSA (total protein 
content of 2.0% w/w of PLGA; Sigma-Aldrich, St. Louis, MO, USA). The above mixture 
was added dropwise to a 3.6x volume excess of an aqueous solution containing 2% (w/v) 
d-α tocopheryl polyethylene glycol 1000 succinate (TPGS; Sigma-Aldrich) under heavy 
vortex. The second emulsion was produced by ultrasonicating on ice for three 
consecutive 15s periods (Omni Ruptor 4000; Omni International; Kennesaw, GA, USA). 
The emulsion was then quickly transferred to a stirring aqueous bath containing 0.2% 
TPGS (10x volume excess; 300rpm) and left undisturbed for 3hrs to undergo solvent 
evaporation. The particles were washed three times by replacing the supernatant with 
deionized water after being centrifuged (Beckman Counter; Allegra 25R; Pasadena, CA, 
USA) at 15,000g for 15mins. The particles were frozen with 25% (w/w) D-(+)-trehalose 
dihydrate; Sigma-Aldrich) and recovered via lyophilization. 
2.2.2. Centrifugal Fractioning  
Following solvent evaporation, PLGA particles were subjected to centrifugal 
fractioning to obtain separate pellet and supernatant sub-groups (Figure 1). A total of six 
groups were used for the study. Fractioning (with varying parameters; Table 1) was 
performed on five groups, whereas the remaining was left unfractioned. Freshly 
fabricated PLGA particles (35.0mg) were resuspended in 0.5mL of deionized water and 
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carefully added atop of 5.5% (w/v) glucose solution with a density of 1.055g/cm3 (5mL; 
Acros Organics, Geel, Belgium). The particles were then size fractioned (Centra CL3R; 
Thermo Fisher Scientific; Waltham, MA, USA) at specified centrifugal forces and spin 
times (Table 2.1). The supernatant and pellet fractions were separated and washed three 
more times with deionized water prior to lyophilization. Subsequent particle size 
analyses, loading and release assays were conducted for all pellet and supernatant sub-
groups and compared to the unfractioned group. 
2.2.3. Particle Size Analysis 
 Particle size analysis was performed via scanning electron microscopy (SEM). 
Briefly, particle samples were extracted from each group after the final deionized water 
rinse and mounted on to carbon tape after lyophilization. They were then coated with a 
gold/palladium sputter coater (108-Auto, Cressington Scientific; Watford, UK) to 
achieve a 5-10nm thick layer of Au/Pd. Samples were subsequently imaged with a 3-5kV 
electron beam (Phillips XL-30; San Francisco, CA, USA).  A minimum of seven regions 
was imaged per particle group. ImageJ (National Institutes of Health, Bethesda, MD, 
USA) was employed to measure the diameter of at least 85 particles for each SEM image; 
thus at minimum 595 particles were measured per sample group that make up the size 
distribution plots. The particle polydispersity index (PDI) was approximated as the 
square of the standard deviation divided by the mean diameter of each group. 
2.2.4. Encapsulation Efficiency 
 Total protein loading was determined by complete dissolution of the particles in 
dimethyl sulfoxide (DMSO; American Bioanalytical, Natick, MA, USA). The DMSO-
polymer solution was then diluted 1:15 in 2.5% (w/v) sodium dodecyl sulfate (Sigma 
Aldrich) + 0.1N sodium hydroxide. The mixture was thoroughly vortexed prior to 
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completing a micro bicinchoninic assay (BCA; G Biosciences; St. Louis, MO, USA) to 
quantify protein using manufacturer’s protocols. Standards were prepared with known 
amounts of soluble BSA supplemented with blank PLGA particles (i.e., no protein 
encapsulated, but produced using identical formulation/fractioning protocols). 
Encapsulation efficiency (EE) was calculated based on the ratio of total protein measured 
versus the total protein added during fabrication.  
2.2.5. Protein Release Assays 
 Lyophilized particles were resuspended in PBS supplemented with 0.01% Tween 
80 and 0.01% NaN3 (8mg/mL) and incubated at 370C under constant agitation. At 
specified time points, the particle suspensions were centrifuged at 14,000g for 15mins 
and supernatant was removed then replaced with fresh PBS. Release media samples 
were collected at the following time points: 1hr, 6hrs, 11hrs, 24hrs, 3d, and subsequently 
at every five days until day 83. The release media from all groups and time points was 
then quantified for protein content using the BCA assay following manufacturer’s 
protocols. 
2.2.6. Statistics  
 All results are depicted as the mean ± one standard deviation, unless otherwise 
noted. Statistical analyses were performed in PRISM (GraphPad Prism, La Jolla, CA) to 
evaluate differences between groups using analysis of variance (ANOVA), and 
multiplicity adjusted p-values are reported for Tukey post-hoc comparisons for 
significance value of α = 0.05. 
2.3. Results 
2.3.1. Centrifugal Fractioning Does Not Affect Particle Morphology and Yield  
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The SEM micrographs indicate that the formulation protocol yields spherical 
particles with a smooth surface morphology and minimal batch-to-batch variability 
(Figure 2.1) [4], [204]. The fractioning protocol did not affect the structural integrity of 
the particles; qualitative differences in particle shape or surface morphology were not 
observed across any of the groups. Total yields for all fractioned sub-groups (pellet + 
supernatant) ranged between 58.5-65.7% relative to 65.1% for the unfractioned group 
indicating that the fractioning process also did not lead to a substantial loss of yield 
(Table 2.1). Collectively, average diameters for all groups evaluated in the study ranged 
between 211-707nm with a PDI between 0.18 - 0.74 (Table 2.1).  
2.3.2. Centrifugal Fractioning Significantly Modulates Particle Size Distribution 
The initial, unfractioned particles exhibited an average diameter of 341nm with a 
poly-dispersity index (PDI) of 0.74. The particle diameters ranged between 60nm and 
2600nm with approximately 93% of the population less than 750nm in diameter (Figure 
2.1A). Upon centrifugal fractioning, we observed a marked change in particle diameter 
distribution (Figure 2.1B). For example, exposing the initial particle population to 550g 
for 10mins resulted in a significantly smaller population in the supernatant with an 
average diameter of 224nm (PDI = 0.33) where 90% of the particles were less than 
400nm in diameter (Figure 2.1B). In contrast, the pellet population for this same 
fractioning protocol exhibited an average particle diameter of 617nm (PDI =0.47) with 
90% of the particles less than 1200nm in diameter (Figure 2.1B). Across the board, 
significant differences in size distributions were observed between the unfractioned 
population and all fractioned sub-groups (pellets and supernatants) with the exception 
of supernatant collected from the lowest centrifugal force with the shortest spin time 
(550g and 2min 15s; Table 2.1). The combination of low spin force (550g) and time 
(2min 15s) likely resulted in an insufficient pellet mass to significantly affect the size 
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distribution in the supernatant. The low pellet yield also meant further analysis of size 
distribution, EE and release profiles were not possible for the 550g, 2:15 pellet group 
(Figure 2.2A). 
2.3.3. Importance of Centrifugation Parameters on Particle Size Distribution 
Five different fractioning protocols were evaluated in this study, resulting in 10 
different particle sub-groups. To compare the size distributions within each sub-group, 
we generated stacked frequency distribution bar graphs to directly visualize specific 
population ranges (Figure 2.2 & 2.3). Nearly half of the population in the unfractioned 
group exhibited diameters below 250nm. Fractioning at a centrifugal force of 550g for 
times ranging from 2:15 to 10:00mins resulted in a significant decrease in the 0-250nm 
particle sub-population in the pellet groups (15-20%; Figure 2.2A). Not surprisingly, we 
observed that the pelleted sub-populations were dominated by particles greater than 
500nm (50-60%; Figure 2.2A). The shift in particle sub-populations resulted in 
approximately doubling of average pellet diameters (ranging between 607-707nm) 
relative to the unfractioned group (341nm). Conversely, we observed a steady increase in 
the smallest 0-250nm sub-population within the supernatant with respect to spin time 
(Figure 2.2B). Specifically, the 10min supernatant fraction had a population distribution 
that was significantly different compared to both unfractioned and shorter spin time 
sup-population groups (Figure 2.2B). Here, we observe the 0-250nm sub-population 
increase by 30%, while less than 5% of the particles were greater than 500nm in 
diameter. Collectively, this population shift resulted in an average diameter of 224nm 
compared to 341nm for the unfractioned group.  
Altering centrifugal force between 550g (‘Low G’) and 1600g (‘High G’) while 
maintaining a constant spin time (10:00mins) yielded significant difference in particle 
size distributions between the pelleted fractions due to nuanced changes in NP sub-
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populations (Figure 2.3A). Specifically, we observed a concurrent shift in two sub-
populations: 250-500nm and greater than 750nm particles. The High G pellet sub-group 
shifted to contain a larger portion of 250-500nm particles (13%) compared to the Low G 
pellet sub-group (Figure 2.3A). Concurrently, the Low G pellet sub-group contained a 
greater number of particles larger than 750nm. No difference in average diameter was 
observed between the supernatant groups (Figure 2.3B). Yet, the PDI was noticeably 
lower for the High G supernatant (0.18) compared to the Low G supernatant fraction 
(0.33; Figure 2.3B) due to the lack of particles greater than 1000nm within the High G 
sub-populations.  
2.3.4. Average Particle Diameter Affects Protein Loading and Release Characteristics 
Upon demonstrating that centrifugal fractioning yields significant differences in 
particle populations, we next investigated the functional effects of average diameter on 
protein loading (encapsulation efficiency) and cargo release profile of our model protein, 
BSA.  We observed marked differences in the encapsulation efficiencies among the 
particle groups, ranging from 36.4% and 49.4% (Table 2.1) with a direct relationship 
between average diameter and the encapsulation efficiency. Additionally, we observed a 
profound impact of particle size distribution on the resulting protein release profile. 
Release profiles for all particle sub-groups described in Figures 2.2 and 2.3 were 
collected and compared; for simplicity, we will conduct three main comparisons to 
highlight the impact of particle size (Figure 2.1 & 2.6) on release profile (Figure 2.4). 
First, we compared fractioned sub-groups with the largest difference in average diameter 
as illustrated by the cumulative frequency plots (Figure 2.6). The unfractioned group 
exhibited a high burst release of 30.3% of total protein in the first 24hrs followed by 
sustained release for 57days (Figure 2.4A). Particle populations with the smallest average 
diameter resulted in higher burst release (49.1%) and shorter total release period 
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(43days; Figure 2.4A). Conversely, the largest average diameter sub-group resulted in a 
lower burst release (15.8%) and longer protein release period (~78days; Figure 2.4A). 
Secondly, the fractioned group with average diameter and size distributions (Figure 
2.6B) most similar to the unfractioned group exhibited comparable release profiles 
(Figure 2.4B). Thirdly, fine-tuning of the release profile based on modest yet statistically 
significant particle diameter distributions (Figure 2.6C) was also achieved (Figure 2.4C). 
The High vs Low G pellet sub-groups exhibited altered burst release (15.8% vs 22.9%, 
respectively) and significant difference in protein release period (63days vs 78days, 
respectively; Figure 2.4C).  
2.3.5. Dependence of Loading and Release Characteristics on Particle Size 
To highlight the key findings from this study, we probed for overarching trends in 
the encapsulation efficiency, burst release, release rate after burst and protein release 
period as a function of average particle diameter (Figure 2.5). Here, encapsulation 
efficiency and protein release period were directly related to average particle diameter, 
whereas, burst release and subsequent protein release rate was inversely proportional to 
average diameter. These findings provide tangible data regarding the direct impact 
particle size alone has on specific release characteristics. Thus, similar fractioning 
techniques may be employed to fine-tune release characteristics without altering sub-
micron PLGA particle formulation parameters. 
2.4. Discussion  
PLGA is one of the most commonly investigated biodegradable polymers for 
applications in drug and protein delivery, where tailoring release profiles for different 
cargo/application settings is critical [187], [205]. In surveying methods to selectively 
tailor release characteristics, one is typically limited to adjusting particle formulation 
parameters to tune specific particle properties (e.g., size, porosity, surface 
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charge/coatings)[163], [190], [196], [197]. Optimization of the release characteristics is 
thus timely and laborious as a minor change in formulation parameters may result in a 
drastic shift in the release profile. Therefore, methods that modulate PLGA particle-
based release properties without changing formulation parameters, such as the protocol 
described here, will reduce time and energy to obtain the desired controlled release 
system.  
Previous studies have reported similar correlations in the encapsulation 
efficiency and release profile relative to PLGA particle average diameter [196], [200], 
[206]–[208]. However, these studies acquired different particle sizes by modifying 
particle formulation parameters that could be expected to confound encapsulation and 
release characteristics. Here, the PLGA particle characteristics were based solely on 
differences in particle size by employing centrifugal fractioning to formulation 
conditions previously established to yield consistent particle size distributions with 
minimal batch-to-batch variability [4], [204]. Our data revealed a direct relationship 
between average particle diameter, encapsulation efficiency and burst release; we also 
observed an inverse relationship between average diameter, protein release rate after 
burst and total release period (Figure 2.5). An example of these trends is illustrated in a 
comparison of the two fractioned sub-groups with a large difference in average diameter 
(High G supernatant and pellet sub-groups). Here, the smaller sub-group (average 
diameter: 211nm) exhibited the lowest observed encapsulation efficiency of 36.4% as 
opposed to 49.4% for the larger particle sub-group (average diameter: 541nm; Table 2.1). 
These results corroborate previous studies that systemically modulated formulation 
parameters to alter average particle diameter where they also report a positive 
correlation between encapsulation efficiency and average diameter[196], [206], [207].  
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Encapsulation efficiency is heavily dependent on the interaction of encapsulated 
agent with the polymer and water during the solvent evaporation stage. Here, the cargo 
is mobile within the dispersed oil (polymer+organic solvent) phase and is thus free to 
diffuse into the continuous aqueous phase [200]. Due to the higher surface area to 
volume ratio of smaller oil droplets, diffusion of hydrophilic proteins across the 
aqueous/organic interface is expected to lower encapsulation efficiency relative to larger 
droplets. As such, the amount of protein encapsulated is expected to relate directly to 
particle diameter, as we observed (Figure 2.5A). Our maximum encapsulation efficiency 
of near 50% is lower than previously reported PLGA micro/nanoparticles that obtained 
80%, however, these studies altered the emulsifier concentration to increase the amount 
of protein loaded, whereas we held this parameter constant throughout the study [196], 
[208].  
The release profiles reported here exhibit an initial burst release followed by a 
roughly zero-order release rate (Figure 2.4). Reported in-vitro release profiles from 
PLGA micro/nano-particles vary greatly, ranging from zero-order to monophasic, 
biphasic and triphasic shapes [188]. Cargo release profiles depend on interactions within 
the particle (i.e., cargo/polymer, cargo/cargo, etc.) and release mechanisms (i.e. 
diffusion, bulk/surface erosion, etc.) that are unique to each particle formulation and 
release conditions [188], [198]. Formulation parameters, such as the type of PLGA 
polymer (i.e., MW, end-group, lactide:glycolide ratio, etc.) and the resulting initial 
particle morphology (i.e., size, porosity and density), determine which mechanisms 
dominate control release rate[197]. Previous studies indicate that reversible interactions 
between BSA and PLGA, particularly for carboxyl end-capped polymers, dominate 
protein encapsulation and release rate properties [188]. Irreversible aggregation or 
adsorption to PLGA polymers/oligomers result in BSA instability and incomplete release 
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[191]. Evaluating protein stability/degradation of released BSA was beyond the scope of 
this study, yet the release assays reliably accounted for at least 90% of the encapsulated 
protein over the course of the release assays (Figure 2.4). In addition to particle 
morphology, population distribution (PDI) is also an important factor in determining the 
overall release profile. For example, Berkland et al. combined particles of various sizes to 
shift the population PDI, resulting in a switch in the release profile of a small, water-
soluble molecule from Fickian to zero-order release[209]. Here, we observed similar 
linear release rates after burst for our particle groups, potentially due to the high PDI 
(PDI <0.1 is considered monodisperse; Table 2.1). In addition, a number of other studies 
report similar release profiles (semi-linear release profile after a burst phase) from 
micro- and nanoparticles[210], [211]. 
 During the early release phase when PLGA particles undergo hydration and 
wetting of the polymer matrix, diffusion dominates the protein release profile. Surface 
adsorbed and loosely immobilized cargo diffuse out rapidly, resulting in the burst 
release[188]. This phase of the release profile is largely correlated with the initial particle 
porosity, cargo properties (size, effective diffusivity, charge, hydrophillicity, etc.) and 
hydration rate of the particle[198]. In addition, particle size also plays a significant role 
in affecting the initial burst release[200]. Increased surface area to volume ratio of 
smaller particles results in a higher burst release, since a greater percentage of the cargo 
is likely to be loosely surface adsorbed and/or pore immobilized in close proximity to the 
surface. Our data support this model whereby we observed a marked increase in burst 
release from the smallest and largest average particle diameter groups (Figure 2.5B). 
Conversely, comparing two NP groups with an average diameter and population 
distribution most similar to each other demonstrated no significant difference in release 
profile (Figure 2.4B). These results suggest that average particle diameter and diameter 
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distributions of particle formulated using identical parameters plays a significant role in 
modulating the burst release. The inverse relationship between burst release and the 
average particle diameter corroborates with general trends reported in literature where 
different micro/nanoparticle sizes were achieved by altering formulation 
parameters[200], [207], [212]. 
Probing further aspects of the release profile, we revealed relationships between 
the average diameter, the total release period and the release rate of BSA after the burst 
phenomenon (Figure 2.5C & D). Release of encapsulated cargo from PLGA particles 
occurs by three mechanisms: 1) transport through the polymer, 2) transport through 
water-filled pores and 3) transport-independent dissolution of encapsulated cargo [188]. 
The rate of water penetration into PLGA matrices is fast relative to the rate of polymer 
hydrolysis, and thus micro/nanoparticles are primarily degraded via bulk instead of 
surface processes [162]. Cargo diffusion through the PLGA matrix is assumed to be 
negligible for all but small, hydrophobic molecules [213]. Thus, after the burst phase and 
particle hydration, release of hydrophilic proteins such as BSA (MW = 66kDa) is 
mediated by diffusion through water-filled pores and is thought to be limited by the rate 
of PLGA degradation/erosion that produces these pores [188]. Specifically, release is 
attributed to the formation, dilation and coalescence of nano-pores (forming mesopores) 
inside the PLGA matrix. Effective protein diffusivity is directly correlated to the size, 
interconnectivity and tortuosity of the pore network, as well as protein/polymer and 
protein/protein interactions[198], [214]. Subsequent diffusion of proteins through these 
pores driven mainly by concentration gradients determines the overall release profile 
following the initial burst. We observed an overall decrease in the rate of protein release 
rate as the average particle diameter increased (Figure 2.5C) potentially due to: 1) 
additional time required to form an interconnected pore network (assuming identical 
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particle porosity & density) and 2) significantly longer diffusion lengths to reach the 
release medium in relatively large particles. Blanco et. al. generated sub-micron PLGA 
particles with diameters ranging between 320-523nm and found that protein release rate 
range between 0.49-1.45% cumulative release per day after burst [207]. Although their 
protein release rates are similar to the ranges reported here (1.01-1.36% cumulative 
release/day), they did not report any discernable trends; likely due to the confounding 
effects of altering formulation parameters. 
Increasing the average diameter of a particle population also led to a longer 
protein release period, most likely due to principles outlined above (Figure 2.5D). In our 
study, the detectable protein release period ranged from 38 days to 75 days relative to 
the unfractioned group that released protein for 57 days (Figure 2.5D). It is important to 
note that the longer diffusion paths of large particles may also result in accumulation of 
acidic PLGA degradation products near the core of the particle, leading to pH-driven 
autocatalytic polymer degradation[198]. The heterogeneous rate of polymer degradation 
and erosion is a proposed mechanism to describe relatively fast cargo release rates for 
some large microparticles and, in some cases, shorter release periods than smaller 
particles [215]. The effects of autocatalytic polymer degradation is much less pronounced 
in smaller particles and does not seem to play an appreciable role for the sub-micron 
particles used in this study[198].  
2.6 Conclusion 
Due to the complexity and the number of interactions involved in determining 
PLGA particle properties, changing formulation parameters to achieve desired loading 
and release characteristics may be time consuming. The methods outlined here 
demonstrate a direct relationship between release properties and the particle population 
size characteristics (distribution and average diameter). Encapsulation efficiency and 
44 
 
several parameters of the release curve (burst release, protein release rate and protein 
release period) correlated to the average diameter of the particle population. Thus 
centrifugal fractioning represents a potential tool for tuning sub-micron PLGA particle 
properties without modifying formulation parameters. Subsequently, centrifugal 
fractioning is useful tool in achieving a desired release profile (such as reducing burst 
release) without potentially compromising other particle attributes due to changes in 
formulation parameters. 
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2.6. Figures 
 
Figure 2.1: Schematic outlining particle preparation protocols and their resulting size 
distributions. A) Unfractioned sub-micron PLGA particles were generated using a 
standard double emulsion technique. B) For the fractioned groups, particles were 
subjected to a centrifugal size fractioning prior to the washing steps where relatively 
small particles comprised the supernatant sub-groups, and larger particles formed the 
pellet sub-groups. Cumulative frequency plots along with their respective histograms 
illustrate significant differences in particle size distributions were achieved without 
necessitating changes to any formulation parameters. All scale bars represent 5μm.  
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Figure 2.2: Spin time alters average diameter and diameter distributions. A) All 
fractioned pellet sub-groups (constant spin force of 550g; Low G) had significantly larger 
diameter distributions relative to unfractioned (UnFrac). Size analysis for the 2:15min 
group was not conducted due to low yield. B) All Low G supernatant sub-groups were 
significantly different relative to Unfrac, except for the 2min 15s group. The 10min 
supernatant group was significantly different compared to the rest of the fractioned 
groups. (* - p<0.01 compared to unfractioned; # - p<0.05 compared to 7min pellet; $ - 
p<0.05 compared to 10min supernatant). 
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Figure 2.3: Spin force affects average diameter and diameter distributions. A) 
Fractioning at 550g (Low G) and 1600g (High G) leads to significant changes between 
Low G and High G pellet sub-groups. B) The supernatant size distributions for both the 
Low and High G groups were significantly different from UnFrac. Although the 
differences between the Low and High G supernatant sub-groups were not statistically 
significant, the PDI is reduced from 0.33 to 0.18. (* - p<0.01 compared to unfractioned; 
$ - p<0.05 compared to 10min supernatant). 
 
Figure 2.4: The protein release profile is dependent on the particle size distribution. A) 
Compares two sub-groups “Small” (1600g supernatant) and “Large” (Large; 550g, 7min 
pellet) with the most significant differences average diameters relative to unfractioned 
(UnFrac). The corresponding release profile from Small exhibited a 50% burst release 
and 40day release period. Large exhibited an 18% burst release followed by a 75day 
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release period. In contrast, UnFrac exhibited a burst release of 30.3% with sustained 
release for 57days. B) Groups with similar particle size distributions also exhibit 
comparable burst release, protein release rate and release period. “Low Spin Time & 
Force Sup” represents the 550g, 2:15min supernatant sub-group. C) Modest, yet 
statistically significant differences in particle size distribution also affects the release 
profile. Significant differences in cumulative protein release were observed at all time-
points except for hours 1, 6 & 11 and days 3, 33 & 48 (p>0.05). 
 
Figure 2.5: Average particle diameter affects (A) encapsulation efficiency, (B) burst 
release, (C) protein release rate after the burst phase, and (D) and total protein release 
period. Encapsulation efficiency and release period was directly proportional to the 
average particle diameter (A and D). Conversely, the magnitude of the burst release and 
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the rate of protein release subsequently were inversely related to average particle 
diameter (B and C). The dotted lines represent 95% confidence interval for all cases and 
a linear regression was used to empirically model the trends for each case. 
 
Figure 2.6: A) Compares the particle size distributions of groups with the most 
significant differences in average diameters. The smallest average diameter particle 
group (Small; 1600g supernatant) contains 90% of the particle population below 400nm. 
The largest average diameter particle group (Large; 550g, 7min pellet) contains 90% of 
the particle population below 1200nm. B) Compares the particle size distributions of the 
two most similar groups; unfractioned (UnFrac) and 550g, 2:15min supernatant (Low 
Spin time & Force Sup). C) Illustrates the modest, yet statistically significant differences 
in particle diameter distributions of High G and Low G pellet sub-groups. 
Table 2.1: Average particle diameters and protein encapsulation efficiencies (EE) are 
significantly altered as a function of centrifugation force and time. Total particle yields 
(pellet+supernatant) was not significantly affected due to the fractioning process. (* and 
# represent p<0.05 in comparison to unfractioned). 
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Unfractioned 
Average 
Diameter 
(nm) 
PDI 
Yield 
(%) 
EE (%)      
341 0.74 65.1 41.8 ±1.6%      
 
 Supernatant Pellet  
Centrifugal 
Force 
Spin 
Time 
(min:s) 
Average 
Diameter 
(nm) 
PDI 
Yield 
(%) 
EE (%) 
Average 
Diameter 
(nm) 
PDI 
Yield 
(%) 
EE (%) 
Total 
Yield 
(%) 
500 (Low) 
2:15 300 0.47 52.7 43.2±0.4%      
3:45 274* 0.37 48.0 41.1±1.1% 607* 0.52 14.0 44.6±0.5% 62.0 
7:00 276* 0.45 38.4 40.4±1.5% 707* 0.37 20.3 48.0±1.1%# 58.7 
10:00 224* 0.33 41.3 38.3±1.0% 617* 0.47 24.4 48.6±0.2%# 65.7 
1600 (High) 10:00 211* 0.18 17.3 36.4±0.5%# 541* 0.47 41.2 49.4±0.1%# 58.5 
 
51 
 
CHAPTER 3 
TUNABLE CONTROLLED RELEASE OF BIOATIVE SDF-1α VIA PROTEIN-SPECIFIC 
INTERACTIONS WITHIN FIBRIN/NANOPARTICLE COMPOSITES 
3.1. Introduction 
 The studies presented in Chapter 2 employed the model protein, BSA, to 
validate protein encapsulation and release from poly(D,L,-lactic-co-glycolic) acid (PLGA) 
particulate devices. The process of developing this generalized protein release platform 
aided in the rational design for the PLGA nanoparticle fabrication protocol best suited 
for SDF-1α encapsulation and release. For example, the protein encapsulation efficiency 
was found to be directly proportional to emulsifier (TPGS) concentration, whereas the 
polydispersity index (PDI) of particle populations was inversely proportional to 
emulsifier concentration. Thus the PLGA particles generated for studies conducted in 
Chapter 2, protein encapsulation efficiency was sacrificed to yield particle populations 
with higher PDI to directly evaluate the relationship between protein release properties 
and the particle population size characteristics. In this current chapter, the focus 
transitioned to optimization and tuning release profiles from SDF-1α loaded PLGA 
particles where the principal difference was an increase of TPGS concentrations both in 
the second emulsion (2.0% vs. 5.0% w/v) and the solvent evaporation phase (0.2% vs 
0.4% w/v). The second major change included the addition of 1.25% (w/v) sodium 
chloride in the solvent evaporation phase that was hypothesized increase in protein 
encapsulation due to osmotic effects [216]. 
 Traumatic brain injury (TBI) is a leading cause of death and disability around the 
world with over 50,000 deaths and an estimated $60 billion in direct and indirect 
economic costs every year, in the United States alone[45]. Although current treatment 
practices have demonstrated some efficacy in treating its long-term effects, there are no 
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means of directly addressing the underlying pathophysiology of TBI [217]. Recent 
studies have reported the activation of endogenous neural progenitor/stem cell (NPSC)-
mediated neurotrophic support and neurogenesis after injury events (e.g. stroke or 
traumatic brain injury) [2], [81], [218]. NPSCs originating from the two adult neural 
stem cell niches (subventricular zone, SVZ; and subgranular zone of hippocampus 
dentate gyrus) selectively migrate to the injury penumbra forming ectopic niches, even 
within non-neurogenic areas of the brain (such as adult cortical tissues)[81], [219]. The 
concentration of the chemokine, stromal cell-derived factor-1α (SDF-1α), and the 
expression of its receptor, CXCR4, increases significantly in the injury penumbra and is 
implicated as a key regulator of directed NPSC recruitment after neural injury[2], [81]. 
However, increased SDF-1α levels subside by 14days post injury, in most reports, 
coinciding with a diminishing number of NPSCs (observed at the injured area) [2], [81], 
[220], [221]. Building on this inherent injury-stimulated signal, we postulate that 
increased and sustained bioavailability of SDF-1α locally in the injury penumbra would 
augment NPSC recruitment and bolster the capacity for endogenous regeneration. 
 With this in vivo application in mind, this study focused on developing a drug 
delivery device for local, sustained release of SDF-1α with the following attributes: 1) 
injectable, 2) biodegradable, 3) prolonged release well past 14days and 4) maintenance 
of SDF-1α levels within the therapeutic concentration range. The most basic form of 
delivering therapeutics is systemic bolus administration. Drawbacks of this method 
include a lack of control over biodistribution due to physiological barriers (i.e. 
endothelial barrier) and rapid systemic clearance[2]. Direct, local injection in the target 
tissue affords control over dosage, but negates temporal control or payload degradation 
leading to only transient therapeutic benefits. Conventional means for local, sustained 
delivery to control both dosage and temporal concentration profile involve bulky, 
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invasive minipump systems that are linked to infections, bleeding and neurologic injury 
[222]. Injectable biomaterials for the controlled release of therapeutics (i.e. hydrogels 
and biodegradable plastics) hold the capacity to overcome the common limitations of 
drug delivery (i.e. dosage, temporal concentration, biocompatibility & patient 
compliance)[1]. Release devices for local and sustained delivery of SDF-1α have been 
explored in several different physiological applications including neural regeneration, 
myocardial infarctions, skeletal regeneration and wound healing[170], [173], [179], 
[223]. However, many of these previous designs were based on hydrogels (such as, 
alginate, collagen, gelatin, star PEG-heparin etc.) and provided sustained SDF-1α for less 
than 14days. Therefore, we sought to tailor a controlled release system that fits the 
aforementioned design criterion, ultimately for neural applications. 
 PLGA, a FDA-approved biodegradable polyester, has long been studied for 
diverse applications in the central nervous system[224], [225]. In addition tunable 
release profiles, a significant benefit of PLGA carriers is insulation of encapsulated cargo 
from the local microenvironment, limiting specific and non-specific degradation and 
leading to increased protein half-life [187]. With a half-life of 25mins in blood, 
maintaining SDF-1α bioactivity was an important parameter for this study [226]. 
Sustained delivery of SDF-1α has been achieved with macro-scale PLGA scaffolds and 
microparticles [172], [180], [185]. Yet, the utility of such macro-to-micro-scale systems 
for minimally invasive delivery is limited. As such, novel nanoscale SDF-1α PLGA-based 
devices are of great interest.  
 The release profiles of encapsulated cargo from PLGA-based particles vary 
greatly (zero-order, monophasic, biphasic and triphasic) depending primarily on 
formulation parameters and typically includes a burst release within the first few hours 
[188]. The PLGA burst phase is problematic since supra-therapeutic concentrations may 
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result in undesired biological consequences. Mechanisms to address the burst issue 
range multilayer coatings to composite system embedding PLGA particles within 
hydrogel matrices. The biologically-derived matrix fibrin has been investigated as a 
carrier for protein delivery [227], [228]. Numerous studies report engineered fibrin-
derivatives crosslinkers to mediate and enhance affinity-based interactions for controlled 
release of a multitude of biologics (e.g. nerve growth factor (NGF), neurotrophin-3, glial-
derived neurotrophic factor, genetic material) [229]–[232]. As a natural extracellular 
matrix (ECM) protein, fibrin possesses inherent ability to bind and sequester soluble 
signaling factors, predominately through a heparin-like binding domains that mediate 
immobilization of small, highly basic (and heparin-binding) proteins such as basic 
fibroblast growth factor (FGF) [233] [153], [234]. Here in this study, we hypothesized 
that embedding SDF-1α-loaded NPs within fibrin matrices will modulate the burst 
release phase due to specific protein-protein interactions between SDF-1α and fibrin. 
The key objectives for this study were to 1) characterize SDF-1α-loaded NPs, 2) probe the 
mechanism of SDF-1α/fibrin(ogen) interactions and 3) determine the effect of SDF-
1α/fibrin(ogen) interactions on SDF-1α release from PLGA NPs. Collectively, we report a 
composite fibrin/PLGA system with the capacity to achieve long-term (60 days), 
bioactive SDF-1α release and the means to independently tune protein release during the 
burst phase. 
3.2. Experimental Methods 
3.2.1. Materials 
Poly(lactic-co-glycolic) acid (PLGA; 50:50 ester-terminated; inherent viscosity = 
0.55-0.75dL/g) was purchased from Lactel (Birmingham, USA). Recombinant mouse 
stromal cell-derived factor-1 α (SDF-1α) were acquired from PeproTech (Rocky Hill, 
USA). B27 growth supplement, DAPI nuclear stain, tetramethylbenzidine (TMB) 
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substrate and Dulbecco's modified eagle medium were acquired from Life Technologies 
(Carlsbad, USA). Glucose was obtained from Acros Organics (Geel, Belgium). High-
binding 96-well enzyme-linked immunosorbent assay (ELISA) plates were acquired from 
Greiner Bio-One (Frickenhausen, Germany). The organic solvent ethyl acetate was 
acquired from Alfa Aesar (Ward Hill, USA) and dimethyl sulfoxide (DMSO) from 
American bioanalytical (Natick, USA). Human fibrinogen (Plasminogen, von Willebrand 
Factor and Fibronectin Depleted), human α-thrombin, human factor XIIIa (FXIII) and 
human plasmin were acquired from Enzyme Research Laboratories (South Bend, USA). 
All other materials and chemicals were purchased from Sigma-Aldrich (St. Louis, USA) 
and used without further modification or purification.    
3.2.2. Formulation of SDF-1α Loaded Nanoparticle 
 SDF-1α loaded PLGA nanoparticles were synthesized using a water/oil/water 
(W/O/W) emulsion technique adapted from a previously published protocol[204]. 
Briefly, the first emulsion (W/O) was obtained by vortexing the oil phase (100 mg/mL 
PLGA in ethyl acetate) with PBS buffer solution (pH = 7.4) containing 20.0mg/mL 
bovine serum albumin (BSA; 2.0% w/w of PLGA) and 2.0mg/mL SDF-1α (0.2% w/w of 
PLGA). The above solution was added dropwise to a 3.6x volume excess of an aqueous 
5.0% (w/v) d-α tocopheryl polyethylene glycol 1000 succinate (TPGS) and the second 
emulsion (W/O/W) was produced by ultrasonicating (Omni Ruptor 4000; Omni 
International; Kennesaw, USA) the solution for two consecutive 15sec periods in an ice 
bath (120W power with a 90% duty cycle). The emulsion was then quickly transferred to 
a stirring (300RPM) aqueous bath containing 0.5% TPGS + 1.25% (w/v) NaCl (10x 
volume excess) and left undisturbed for 3hrs for solvent evaporation. The particle 
suspension was washed three times with deionized water by centrifugation at 15,000g 
for 15min in between rinses (Beckman Counter; Allegra 25R; Pasadena, USA). The 
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particles were supplemented with 25% (w/w) D-(+)-trehalose dihydrate and recovered 
through lyophilization. Particle size analyses were performed by scanning electron 
microscope (SEM; Phillips XL-30; San Francisco, USA) using a 3-5kV electron beam. 
Lyophilized particle samples were prepared for SEM analysis via gold/palladium sputter 
coater (108-Auto, Cressington Scientific; Watford, UK) to achieve a 5-10nm thick layer. 
A minimum of 7 images were captured per group and were processed using ImageJ to 
determine the size distributions. At least 85 sampling points were required for each 
image and thus size distribution histograms are comprised of a minimum of 595 
measurement points in total. 
3.2.3. Protein Loading & Release Assays 
 Total protein loading was determined by complete dissolution of a known 
amount of particles (10 mg/mL) in dimethyl sulfoxide (DMSO). The DMSO solution was 
then diluted 1:15 using 2.5% (w/v) sodium dodecyl sulfate and 0.1N NaOH in deionized 
water. The mixture was thoroughly agitated, being careful not to introduce bubbles. 
Known amounts of soluble BSA added to blank particles (no protein encapsulated; 
synthesized using identical synthesis protocols) were used to generate calibration curve. 
Protein quantification was performed using bicinchoninic assay (BCA; G Biosciences; St. 
Louis, USA) in triplicates following manufacturer’s protocols. Encapsulation efficiency 
and loading capacity were calculated using the following:  
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) = 100 ∗ (
𝑇𝑜𝑡𝑎𝑙 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (𝑚𝑔)
𝑇𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑑𝑑𝑒𝑑 (𝑚𝑔)
) 
𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝐶𝑎𝑝𝑎𝑐𝑖𝑡𝑦 (%) = 100 ∗ (
𝑆𝐷𝐹 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑖𝑛 𝑁𝑃𝑠 (𝑚𝑔)
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑁𝑃𝑠 (𝑚𝑔)
) 
For the release assays, lyophilized particles were resuspended in 1 mL of buffer 
release media (1x PBS supplemented with 0.01% tween 80 and 0.01% NaN3) at 
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3.5mg/mL and incubated at 370C under constant agitation. At specified time points, the 
supernatant was collected by centrifuging the particle suspension at 14,000g for 15mins, 
collecting 90% of the supernatant and replenishing with fresh buffer release media. 
Extracted buffer release media samples were stored at -800C for subsequent protein 
analysis. To specifically determine the SDF-1α content, a known concentration 
(500ng/mL) was incubated alongside the NP suspension as a positive control for 
subsequent analysis using ELISA-based detection (R&D systems; Minneapolis, USA). 
NPs with no encapsulated SDF-1α served as the negative control.   
3.2.4. SDF-1α Bioactivity Assay 
3.2.4.1. Neural Progenitor/Stem Cell Harvest and Culture 
 Murine fetal derived neural/progenitor stem cells (NPSCs) were isolated from the 
medial and lateral germinal eminences of E14.5 C57BL/6 mice based on previously 
published protocols and in accordance with approval by the Institutional Animal Care 
and Use Committee at Arizona State University[235]. The germinal eminences were 
harvested, mechanically disassociated and cultured in NPSC medium (Dulbecco's 
modified eagle medium (DMEM:F12) with 2.4mg/mL sodium bicarbonate (NaHCO3), 
6 mg/mL glucose, 5mM HEPES, 62.9 ng/mL progesterone, 9.6 μg/mL putrescine, 
1.83 μg/mL heparin, 1X B27 growth supplement, 20 ng/mL epidermal growth factor 
(EGF), 5 ng/mL FGF, 5 μg/mL insulin, 5 μg/mL transferrin, and 5 ng/mL sodium 
selenite). NPSCs were cultured as non-adherent neurospheres and used for 
experimentation between passages 3-6.  
3.2.4.2. Modified Boyden Chamber Assay 
 NPSC chemotaxis in a modified-Boyden chamber assay was used to determine 
SDF-1α bioactivity as previously described[12]. In short, disassociated NPSCs were 
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plated (70,000 cells/cm2) on laminin-coated transwell inserts with 12µm pore diameter 
(Millipore, Temecula, CA). Growth factor-free NPSC medium (no EGF or FGF) with 0 or 
250ng/mL SDF-1α (negative and positive control, respectively) was added in the bottom 
chamber. NPSCs were then allowed to undergo chemotaxis for 24hrs in an incubator 
(370C and 5% CO2). Subsequently, cells on the top side of the transwell membrane were 
removed using a cotton swab whereas migrated cells that reached the bottom were fixed, 
underwent a DAPI nuclear stain and imaged. NPSC nuclei have diameters of 
approximately 20µm[236]. After intensity thresholding, nuclei count was quantified 
using a particle count algorithm in ImageJ where stained nuclei 10-30µm in diameter 
were counted as individual cells. Nuclei count was determined by imaging and 
quantifying whole transwell membranes.  
3.2.4.3. Bioactivity of Encapsulated SDF-1α 
The bioactivity of the encapsulated/released SDF-1α from PLGA NPs was 
evaluated at two timepoint intervals (day 0-1 and day 20-22) via the modified Boyden 
chamber assay described above. Release samples were acquired from blank and SDF-1α-
loaded NPs resuspended in cell culture release media (DMEM:F12 supplemented with 
2.4mg/mL NaHCO3); the NP concentration for day 0-1 interval was 9.0mg/mL versus 
17.5mg/mL for day 20-22 to account for variation in the amount of SDF-1α released 
during the burst or sustained release phases. The NP suspensions were incubated at 370C 
with agitation, taking precautions to maintain sterility. For the day 20-22 interval, the 
cell culture release media was exchanged every 3days until day 20. After the specified 
incubation period, NPs were centrifuged (14,000g for 15mins) to collect the supernatant, 
and the modified Boyden chamber assay was carried out immediately. NP cell culture 
release media was diluted 1:10 and 1:2 for day 0-1 and day 20-22 samples, respectively, 
with growth factor-free NPSC media to achieve a SDF-1α concentration in the NPSC 
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chemotactic range (Figure 3.2). The dilution factors were estimated via a preliminary 
total protein release profile (data not shown). A minimum of 4 replicates per group 
performed for all migration assays.  
3.2.5. SDF-1α-Fibrin(ogen) Binding Detection ELISAs 
 SDF-1α-fibrinogen interaction were probed by adapting a previously described 
modified ELISA[153]. SDF-1α, BSA and basic fibroblast growth factor (FGF) were coated 
on high-binding ELISA plates by incubating the soluble factors at 100nM (in 100mM 
carbonate buffer; pH 9.6) for 3hrs at 370C. All growth factor (GF) coated wells were 
blocked using 2.0% (w/v) fat-free powdered milk in PBS for 1hr at room temperature 
(RT). Fibrinogen (35µg/mL; depleted of fibronectin, plasminogen, and von Willebrand 
factor) was incubated for 1hr at RT. The primary antibody (rabbit anti-fibrinogen; EMD 
Millipore; Darmstadt, Germany) was then added for 1hr at RT, followed by the secondary 
antibody (HRP conjugated goat anti-rabbit IgG; Thermo Scientific; Waltham, USA), also 
under the same conditions. Detection was carried out TMB substrate following 
manufacturer’s protocols. Four washes were performed in between each of the steps 
mentioned using PBS with 0.01% Tween-20 (PBS-T). Heparin competition ELISAs were 
also performed with various concentrations (0.75 – 200µg/mL) of soluble heparin (17-
19kDa), which was supplemented in the fibrinogen solution after the blocking step 
mentioned above[153]. All subsequent steps were kept identical.  
The next modified ELISA probed SDF-1α interactions with fibrin. A previously 
described protocol was adapted to generate a thin layer of fibrin network on high-
binding ELISA plates[237]. In short, fibrinogen (depleted of fibronectin, plasminogen, 
and von Willebrand factor) was incubated at 100µg/mL for 1hr at RT. After rinsing three 
times with Tris-buffered solution (10mM Tris + 150mM NaCl), the wells were blocked 
using 1.0% (w/v) BSA for 20mins at RT. After rinsing, human thrombin (2.5 NIH U/mL) 
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and human FXIIIa (0.5 NIH U/mL) was added and incubated for 15mins at RT. Fibrin 
coating was completed after washing and subsequent incubation with fibrinogen 
(500µg/mL), anti-thrombin-III (50µg/mL) and heparin (60µg/mL) for 1hr at RT. The 
plates were then washed and stored with 2.0% (w/v) powdered milk in PBS overnight at 
40C. Control groups included wells that were coated with heparin (70µg/mL; positive 
control) or BSA (1.0 mg/mL; negative control) in PBS, overnight at 40C. Surface-
modified wells were then exposed to various concentrations of SDF-1α (0-20µg/mL) for 
1hr and relative levels of SDF-1α binding were measured using rabbit anti-SDF-1α 
(Abcam; Cambridge, USA), HRP-conjugated goat anti-rabbit and TMB substrate. A 
minimum of n=3 was used for all ELISAs. 
3.2.6. SDF-1α Release from Fibrin Matrices 
 Release of soluble SDF-1α from fibrin matrices was conducted as described 
previously[153]. In short, fibrin gels were generated with fibrinogen (3 or 25mg/mL), 
human thrombin (5U/mL), human FXIIIa (2.5U/mL), calcium chloride (5mM) and 
SDF-1α (500ng/mL) in TBS. The fibrin matrices (150µL) were polymerized (by 
combining separate fibrinogen and thrombin solutions) for 1hr at 370C under sterile 
conditions in ultra-low binding 24-well plates. After the polymerization, 700µL of TBS 
(with 0.1% w/v BSA) was added to initiate the release assay. The release buffer was 
extracted, stored in -800C and replaced with fresh TBS every 24hrs for 7days. On Day 7, 
the fibrin matrices were digested with plasmin (0.5U/mL) to quantify the remaining 
SDF-1α. A control group consisted of soluble SDF-1α (500ng/mL) where 30µL was 
extracted for every timepoint and also underwent the plasmin treatment. SDF-1α content 
was determined via SDF-1α ELISA. All groups were measured in triplicates.  
3.2.7. Release Assay from SDF-1α-Loaded NPs Embedded in Fibrin 
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 Fibrin gels (3, 10, 25mg/mL) were formed using the same procedure as above 
where free SDF-1α was replaced by PLGA NPs (blank and SDF-1α-loaded NPs) with a 
final concentration of 1mg PLGA NPs/1mL of fibrin gel. Similar to the previous release 
assay, fibrin matrices (150µL) were formed in ultra-low binding 24-well plates for 1hr at 
370C under sterile conditions, after which 700µL of TBS (with 0.1% w/v BSA) was added. 
The release media was extracted, replaced and stored at hours 1, 3, 6, 12, 24 48 and 72 
after initiating the release assay. SDF-1α content in all timepoints were quantified via 
ELISA. A 500ng/mL SDF-1α group as served as the control groups, where similar to 
before, 30µL was extracted at every timepoint. All groups were tested in triplicates.  
3.2.8. Physical Characterization of Fibrin/NPs Composite 
 Fibrin polymerization was monitored with time-dependent optical density 
measurements (Epoch; Biotek; Winooski, USA). Control (native fibrin clots with no NPs) 
and NP-embedded gels (0.1, 1 & 10mg/mL) were prepared using the same parameters as 
mentioned earlier. Three different fibrinogen (3, 15 & 30mg/mL) groups were tested 
where optical density (OD) was measured every 30sec for 2hrs in triplicate per group. 
Terminal clot turbidity refers to the OD at the end of 2hrs. 
 Percent clottable protein was quantified for control and experimental fibrin gels 
(with NPs; 0.1, 1 & 10mg/mL; n= 3). The fibrinogen content before polymerization was 
compared to the remaining soluble fibrinogen that remained following fibrin gel 
formation (40min) [238]. Fibrinogen (FBN) content in the remaining solution (clot 
liquor), taking into account the presence of additional enzymes, was measured using 
BCA where percent clottable protein (CP) is defined as the following: 
𝐶𝑃(%) =  100 ∗ (
𝐹𝐵𝑁𝐼𝑛𝑖𝑡𝑖𝑎𝑙(
𝑚𝑔
𝑚𝑙
) − 𝐹𝐵𝑁𝐶𝑙𝑜𝑡 𝐿𝑖𝑞𝑢𝑜𝑟 (
𝑚𝑔
𝑚𝑙
)
𝐹𝐵𝑁𝐼𝑛𝑖𝑡𝑖𝑎𝑙  (
𝑚𝑔
𝑚𝑙
)
) 
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                  The mechanical properties of the fibrin gels were also analyzed with an 
oscillatory parallel-plate geometry rheometer (MCR 101; Anton Paar; Ashland, USA). 
Fibrin clots (3 & 30mg/mL) with and without NPs (0.1, 1, 10 mg/mL) were generated 
with identical protocols as described above. The fibrin gels (0.4mL) were polymerized 
within a 400μm gap between the top and bottom plates (1hr at 370C under high 
humidity). A strain sweep (0.01 to 100%) was performed to determine the linear 
viscoelastic regime for all concentrations of fibrin and strain amplitude of 1% was chosen 
for all subsequent frequency sweep tests (0.01-100Hz) to determine storage (G’) and loss 
(G’’) modulus (n = 2)  
3.2.9. Statistics 
 Statistical analysis was performed on all quantitative assays. All results are 
depicted as the mean ± one standard deviation, unless otherwise stated. Statistical 
analyses (GraphPad Prism, La Jolla, CA) evaluated differences between groups using 
analysis of variance (ANOVA) followed by Tukey post-hoc tests to determine statistical 
significance with p < 0.05 considered significant. Multiplicity adjusted p-values are 
reported for Tukey post-hoc comparisons. 
3.3. Results and Discussion 
3.3.1. Characterization of SDF-1α Loaded NPs 
 SDF-1α was successfully encapsulated in PLGA NPs using a double emulsion 
method. Characterization assays included size analyses via SEM micrographs, total 
protein encapsulation efficiency as well as quantification of SDF-1α release profile 
(Figure 3.1). Resulting NPs were spherical in shape and had smooth surface morphology 
with an average diameter (± standard error of mean; SE) of 288.9 ± 19.2 nm, 
comparable to previously reported PLGA NPs[204], [239]. The reported average NP 
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diameter was an average of 5 separately prepared batches. The NP population 
distribution for each batch consistently ranged between 100-1500nm with 90% of the 
NPs falling within 200-600nm (Figure 3.1C). NP size distributions were statistically 
consistent between batches and NP yields ranged between 57-65%, indicating minimal 
batch-to-batch variability. The total protein (BSA+SDF-1α) encapsulation efficiency for 
the resulting NPs was 61.7% ± 2.8%. Attempts to determine SDF-1α loading using 
conventional methods requiring dissolution of NPs in an organic solvent followed by 
protein extraction and quantification via SDF-1α ELISA proved unreliable due to protein 
denaturation and degradation; this issue was also previously reported by Cross et. al. 
[180]. As a result, we estimated total encapsulated SDF-1α via cumulative values from 
the SDF-1α ELISA release profile (Figure 3.1D). SDF-1α content measured during the 
release assay amounted to a total SDF-1α loading capacity of 293ng of SDF-1α/1mg of 
PLGA (i.e. 0.029±0.00076% (w/w) PLGA NPs). Furthermore, the NPs exhibited a tri-
phasic release profile, frequently observed in PLGA-based release devices[188]. We 
observed sustained release of SDF-1α for 60 days following an initial burst release and a 
lag phase approximately between days 2 and 6 (Figure 3.1D). In the first day, the NPs 
release 67ng SDF-1α for every 1mg of PLGA NPs, which translates to a burst release of 
23% total released SDF-1α as determined by ELISA. 
 PLGA-based release systems devices are unique since cargo release rate is largely 
controlled by polymer degradation rate and thus is not purely diffusion-mediated[188]. 
The release profile is a result of various interactions (i.e. cargo/polymer, cargo/cargo 
etc.) and release mechanisms (i.e. diffusion, bulk erosion etc.) that are relevant to a 
particular set of particles145144(Hines and Kaplan, 2013)9. After the burst release, the 
mechanism of release for hydrophilic proteins is attributed to the formation, dilation and 
coalescence of nano-pores (forming mesopores) inside the PLGA matrix [162]. The 
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effective protein diffusivity is directly correlated to the properties of the pore network 
and protein/polymer interactions. Thus prolonged release in the later stages is mediated 
by polymer degradation and erosion as well protein diffusion. As a result, choice of PLGA 
was a rational decision considering our goal for achieving long-term, sustained and 
bioactive SDF-1α release. 
 Previous studies demonstrated the feasibility of encapsulating and releasing 
bioactive SDF-1α (as tested by in vitro mesenchymal stem cell migration) from PLGA 
microparticles to achieve controlled release over 40-70days [180], [185]. However, both 
studies report relatively low SDF-1α loading. The PLGA microparticles in one study 
indicated a loading capacity of approximately 0.0018% (w/w) of PLGA, whereas the 
other had a theoretical maximum of 0.002% (w/w) SDF-1α relative to PLGA polymer. A 
low loading capacity equates to a requirement of high amounts of PLGA. Thus achieving 
adequate, therapeutic levels of SDF-1α may conflict with the accumulation of acidic 
byproducts that affects the local pH[163]. In comparison, we report PLGA nanoparticles 
with loading capacities of SDF-1α an order of magnitude higher at 0.029% (w/w) PLGA. 
Additionally, we achieved SDF-1α controlled release for 60 days, meeting our initial 
design criterion (Figure 3.1D). 
3.3.2. NPSC Migration Assays Indicate Release of Bioactive SDF-1α 
 Modified-Boyden chamber migration assays were utilized to measure functional 
SDF-1α bioactivity (Figure 3.2A, B).  SDF-1α is known to elicit a biphasic migratory 
response in vitro with a number of cell types (NPSCSs, mesenchymal stem cells; MSCs, 
leukocytes, hematopoietic cells etc.) over a wide range of concentrations (10-
1000ng/mL) [12], [36], [41], [241]–[243]. This biphasic migratory response reportedly 
relates to the internalization of CXCR4 upon interaction with SDF-1α. Overstimulation 
from high concentrations of SDF-1α may lead to desensitization to the chemokine[241], 
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[244]. In our hands, the maximal NPSC migration response occurred at 250ng/mL after 
24hrs and revealed a biphasic relationship to SDF-1α concentration where 1000ng/mL 
did not elicit any chemotactic response above the basal media levels (Figure 3.2B). The 
biphasic response of SDF-1α on NSCs suggests control over SDF-1α dosage and its 
temporal concentration profile is required to achieve a desired biological response. 
 The W/O/W double emulsion synthesis for PLGA NPs inherently involve harsh 
conditions such as water-oil interfaces, ultrasonication, freeze thaw cycles and 
lyophilization, known to affect the structural integrity and the biological properties of 
proteins[191]. Additionally, detection of SDF-1α via ELISA does not necessarily equate to 
functional bioactivity since the epitope recognition site for ELISA can vary from the 
biologically relevant site(s). As a result, the Boyden chamber assay described above was 
used to measure functional bioactivity of SDF-1α encapsulated in and released from the 
NPs. For each time interval (day 0-1 & days 20-22), 250 ng/mL SDF-1α and 0ng/mL 
served as the positive and negative controls for NPSC chemotaxis, respectively. In 
addition, release media from blank NPs were used as a control for confounding affects 
from PLGA degradation products. 
 The release media from day 0-1 elicited a robust migratory response that was 
significantly higher than both the negative control (no SDF-1α; p = 0.0007) and the 
blank NP group (Figure 3.3A, B; p = 0.0201). No adverse effects on NPSC chemotaxis 
were observed with the blank NP group for the 24hr incubation period, agreeing with 
previously published results with MSCs[180]. The data suggests that bioactivity of SDF-
1α is not significantly altered with the NP synthesis protocol. The day 0-1 release media 
is largely composed of the burst phase that accounts for loosely adsorbed SDF-1α on the 
NP surface that diffuse out rapidly upon particle hydration. However, preservation of 
protein bioactivity in the first day does not indicate sustained release of bioactive 
66 
 
protein. Local pH within the particles have been reported to be <pH 3 and during 
release, the cargo can undergo aggregation, non-reversible adsorption and degradation 
leading to further loss in bioactivity and incomplete release[191]. Thus release media 
from day 20-22 was also evaluated to validate maintenance of bioactive SDF-1α (Figure 
3.3A, C). Here, NPSC migration significantly increased in the SDF-1α-loaded NP group 
relative to blank NPs, which controlled for potential confounding affects from the acidic 
PLGA degradation products (p<0.05). A similar trend was observed in the pairwise 
comparison to the negative control, though not statistically significant (p=0.0599). In 
summary, encapsulation of SDF-1α in the NPs maintained the long-term bioactivity of 
SDF-1α. Moreover, encapsulated cargo is insulated from biological proteolytic factors in 
future in vivo applications. Thus we postulate this device has the potential to improve 
SDF-1α half-life (25mins in blood) as shown with other proteins in vitro and in vivo 
[187], [191]. 
3.3.3. Protein-protein Interactions between SDF-1α and Fibrin(ogen) 
 The high burst release from the NPs within the first hours is a concern 
considering biphasic response to SDF-1α (i.e. decreased NPSC migration; Figure 3.2). 
Moreover, high SDF-1α concentrations in vivo reportedly initiate systemic immune cell 
recruitment and infiltration [25]. Modest decrease of NP burst release magnitude may be 
achieved through alterations of the NP formulation parameters [200], [245]. However, 
changes in synthesis conditions create complex, multifaceted interactions that affect 
several particle properties at once. For example, changing polymer concentration not 
only affects encapsulation efficiency and loading capacity, but it also influences particle 
size and porosity, key factors determining release rate and duration [200], [246]. 
Therefore, we pursued a composite system as it affords the ability to independently tune 
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the release profile without compromising the desired attributes already attained by the 
NPs (sustained release of bioactive SDF-1α).  
 Composite biomaterials with drug carriers embedded in hydrogels has been 
explored for a number of applications [158], [247], [248]. One relevant example includes 
basic fibroblast growth factor (FGF)-loaded nanoparticles embedded in fibrin to achieve 
tunable ,zero-order release with the ability to reduce/eliminate the burst phenomenon 
[158]. The presence of heparin-like binding domains in the structure of native fibrin and 
its monomer, fibrinogen, is correlated to specific binding with highly basic, heparin-
binding proteins such as FGF, vascular endothelial growth factor (VEGF), placenta 
growth factor-2 (PIGF-2) and insulin-like growth factor-binding protein-3 [153], [234], 
[249]. Due to the similarities in molecular weight, isoelectric point and heparin binding 
capacities between known fibrin-binding proteins such as, FGF, and SDF-1α, we probed 
the existence of fibrin(ogen)/SDF-1α interactions. 
 Fibrin(ogen)/SDF-1α interactions were determined using three modified ELISAs 
that probed both fibrin/fibrinogen affinity as well as, mechanistic competition with 
soluble heparin (Figure 3.4). First, the fibrinogen binding assay consisted of 
investigating soluble fibrinogen binding to adsorbed soluble factors (BSA, negative 
control; FGF, positive control; or SDF-1α). The results demonstrated a significant 
increase in fibrinogen binding/retention on SDF-1α-coated wells relative to BSA-coated 
wells (Figure 3.4A, B; p<0.05).  More importantly, the fibrinogen retention levels for 
SDF-1α were comparable to the positive control FGF-coated wells, suggesting a binding 
interaction between SDF-1α and fibrinogen (Figure 3.4A, B). 
  The second ELISA assay probed the mechanism of SDF-1α/fibrinogen 
interaction. The heparin-like binding domain in fibrinogen is located in the first 66 
amino acid residues of the Bβ chain [153], [250]. The high concentration of arginine and 
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lysine residues in that region allows promiscuous binding to both soluble factors and 
heparin [153]. Thus, a competition ELISA was performed where known amounts of 
soluble heparin (0.75-200µg/mL) was added to compete with the heparin-like binding 
domains on fibrinogen. The results indicate significant attenuation of signal with 
increasing heparin concentration for both FGF and SDF-1α–coated plates (Figure 3.4C). 
Conversely, signal from the BSA-coated wells do not exhibit a similar dependence on 
heparin content. The trends observed in Figures 3.4B and 3.4C agree with data from 
similar assays reported for other known fibrin-binding proteins [153]. Thus, the 
observed fibrinogen/SDF-1α interaction cannot be attributed to non-specific 
interactions, but most likely due to specific SDF-1α/fibrinogen interactions via the 
heparin-binding domain.  
 The final ELISA probed SDF-1α interactions with the insoluble, polymerized 
fibrin after a thin layer was deposited on ELISA plates [237]. Concentration dependent 
retention of SDF-1α on both, heparin-coated (positive control) and fibrin-coated wells 
relative to BSA-coated negative controls, indicate that specific SDF-1α/fibrinogen 
interactions are maintained when fibrinogen polymerizes to form fibrin (Figure 3.4D, E). 
Collectively, the results from these modified ELISA assays indicate specific protein-
protein interactions between SDF-1α and fibrin(ogen) exists primarily via SDF-1α 
interactions with the heparin binding domain. 
3.3.4. Fibrin Sequesters Free SDF-1α 
 Affinity-based interactions via the heparin-like binding domains on fibrin(ogen) 
is hypothesized to play a major role in determining growth factor release profile. For 
example, soluble heparin binding factors such as PIGF-2, FGF and VEGF exhibit 
prolonged release and sequestration in native fibrin matrices while, VEGF121 (isoform 
lacking the heparin-binding domain) and NGF are released in a more diffusion-limited 
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manner [153], [228], [234]. Although fibrin density, fiber length and fiber aspect ratio 
are important determinants of release profile, evidence of immobilization/ sequestration 
(slow or no protein release) is a key indicator for affinity-based interactions playing a 
dominant role in determining release rate. For example, PIGF-2-loaded fibrin gels 
release ~15% of cumulative cargo in the first 2 days, whereas the remaining cargo was 
sequestered in the fibrin matrix for at least 7 days[153]. In contrast, NGF (low fibrinogen 
binding affinity) encapsulated in an identical fibrin matrix exhibited 100% cumulative 
release within 2 days [153]. Additionally, Wong et al. reported a similar release profile 
for FGF and concluded that diffusion-only release mechanism cannot account for cargo 
sequestration observed [234].  
 Building on the SDF-1α-fibrin(ogen) ELISA assays (Figure 3.4), we conducted 
SDF-1α release assays from fibrin gels to evaluate ability of the protein-protein 
interactions to sequester SDF-1α within three-dimensional fibrin matrices. We also 
evaluated the effects of fibrin density on SDF-1α release profile with the hypothesis that 
altering the number of available binding sites will dictate the maximal amount of 
sequestered SDF-1α within fibrin matrices [251]. We must note that altering fibrin 
density also modifies various matrix morphological properties and thus diffusion-limited 
cargo release profile; however, our experiment was designed to focus specifically on the 
sequestration of SDF-1α within a short 7 day release period (Figure 3.5). Thus, two 
concentrations of fibrin were evaluated, 3mg/mL (physiologically relevant 
concentration) and 25mg/mL gels loaded with a constant mass of SDF-1α (500ng/mL). 
The release study indicates that 90% of the encapsulated SDF-1α was released after 2 
days in the 3mg/mL group whereas only 20% of the SDF-1α was released from the 
25mg/mL group within that same time frame (Figure 3.5A). More interestingly, SDF-1α 
release between days 2-7 was undetectable using ELISA, suggesting sequestration of 
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residual SDF-1α not immediately released within the first 2 days. After 7 days, fibrin 
clots were digested with plasmin, a serine protease, to liberate immobilized SDF-1α for 
quantification. Cumulative detection of released SDF-1α in combination with SDF-1α 
recovered after fibrin digestion was similar to the initial payload for both groups (Figure 
3.5B). Thus, the plateau in the SDF-1α release profile after the first 2 days strongly 
suggests that SDF-1α was captured and sequestered in fibrin matrices. The amount of 
SDF-1α sequestered was proportional to fibrin density as expected, where the 3mg/mL 
group was only able to sequester roughly 10% of the encapsulated SDF-1α. Additionally, 
The SDF-1α release profile from fibrin was comparable to previously reported for release 
kinetics for soluble FGF from fibrin [153], [234].  
3.3.5. Fibrin Modulates SDF-1α Burst Release from PLGA NPs 
 Given the interaction uncovered between SDF-1α and fibrin(ogen), we evaluated 
potential modulation of NP release profile. Specifically, we aimed to determine the effect 
of embedding SDF-1α-loaded NPs in different fibrin densities on the burst release in an 
idealized in vitro release assay. This experiment only focused on the first 72hrs to fully 
capture the kinetics of the burst phenomena. The same concentration of NPs (1mg of 
PLGA / 1mL of fibrin) was embedded within three different fibrin clot densities (3, 10 & 
25mg/mL). The resulting SDF-1α release profiles were strongly dependent on the fibrin 
concentrations (Figure 3.6A). Specifically, NPs embedded in 25mg/mL clots reduced the 
amount of detected SDF-1α by ~55% after 24hrs compared to NPs freely suspended in 
buffer. The total cumulative released SDF-1α was significantly reduced in the 10mg/mL 
(p<0.01) and 25mg/mL (p<0.01) groups after 72hrs in comparison to free NPs (Figure 
3.6B). Additionally, difference in total protein released between the 25mg/mL, and both 
3mg/mL (p<0.01) and 10mg/mL (p<0.01) groups was also statistically significant. 
Although, total SDF-1α detected in the 3mg/mL group was not significantly different 
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(compared to free NPs) after 72hrs, cumulative SDF-1α dosage was 25% lower after the 
first 10hrs upon addition of fibrin. Therefore, these data suggest the following, 1) 
amplitude of the NP burst may be tuned by exploiting SDF-1α/fibrin interactions and 2) 
embedding the NPs within fibrin gels of varying concentrations controls the amount of 
SDF-1α released within the first 72hrs in vitro, under idealized conditions. 
3.3.6. PLGA NPs Do Not Significantly Alter Fibrin Polymerization 
 Fibrin (with and without NPs) matrices were assessed by measuring clottability 
of fibrinogen monomer, end-point turbidity and rheological characterization of 
viscoelastic properties. Our data suggests that the presence of NPs (up to 10mg/mL) 
does not significantly disrupt the formation of fibrin (Figure 3.7A). As a result, end-point 
turbidity of fibrin clots was also similar between native and NP-embedded gels for the 15 
& 30mg/mL fibrin groups (Figure 3.7B). The differences observed for the 3mg/mL group 
was due to the presence of the NPs themselves (data not shown). Rheological studies 
further support that fibrin clot integrity was maintained upon addition of NPs (Figure 
3.7C and D). The low-frequency plateau in the storage modulus (G’) of both 3 & 
30mg/mL fibrin groups indicate polymerization of fibrinogen to form viscoelastic fibrin 
(Figure 3.7C) [252]. Additionally, the overall characteristics of the storage and loss 
moduli was not altered upon adding 10mg/mL NPs in either 3 or 30mg/mL fibrin 
matrices (Figure 3.7C). The overall strength of fibrin was not dependent on NP content 
for the 3mg/mL fibrin group. Although statistically significant changes in G’ was 
observed for 30mg/mL fibrin group with 1 & 10mg/mL NP (Figure 3.7D), the two-way 
ANOVA indicates that overall, NP concentration is not a significant determinant of fibrin 
storage modulus (p=0.086). Overall values for G’ acquired for the fibrin groups were 
similar to other reports in literature for native fibrin [252]–[254]. 
3.5. Conclusion 
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 Here, we report successful encapsulation of SDF-1α within PLGA NPs to achieve 
controlled release over 60days. Functional bioactivity of encapsulated and released SDF-
1α was demonstrated through in vitro NPSC chemotactic migration assays. However, 
careful control over time-dependent SDF-1α concentration is crucial in eliciting desired 
therapeutic outcome. We determined that SDF-1α was successfully sequestered in fibrin 
clots and that NPs embedded in different concentrations of fibrin controlled the 
magnitude of the burst release profile without negatively affecting fibrin matrix 
properties. These results are significant in potentially obtaining local and sustained 
release of SDF-1α in a neural injury site to amplify and/or sustain NPSC-mediated 
endogenous repair response.   
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3.6 Figures 
 
Figure 3.1: SDF-1α NP Characterization: (A, B) Representative SEM images of SDF-1α 
loaded NPs depicting smooth, spherical particles; scale bars = 2µm. (C) Histogram 
illustrating the size distribution of NPs with a range between 100-1500nm and where 
90% of the population is between 200-600nm in diameter. (D) In vitro release assay 
measured with SDF-1α ELISA demonstrated sustained SDF-1α release for 60 days. The 
inset illustrates the initial burst release of 23% of total measured SDF-1α within the first 
24hrs. 
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Figure 3.2: Soluble SDF-1α elicited a biphasic migration response in a Boyden chamber 
assay. (A) Schematic depicting the Boyden chamber setup where cells that were seeded 
in the top chamber migrates to reach the bottom side through chemotactic migration 
after 24hrs. (B) NPSC chemotactic migration demonstrates a biphasic response where 
the 250ng/mL group is significantly different compared to both to baseline and 
1000ng/mL SDF-1α group. (* represents p<0.05 relative to 0ng/mL SDF-1α); $ 
represents p<0.05 relative to 250ng/mL). 
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Figure 3.3: Bioactive SDF-1α Released from NPs. (A) Release media from day 0-1 and 
20-22 were evaluated for bioactivity via NPSC chemotaxis assay. (B) Chemotactic 
response from NPSCs incubated with release media from day 0-1. SDF-1α-loaded NPs 
(‘SDF NP’) elicits a significant increase in nuclei count relative to both blank NPs and the 
negative control. (C) NPSC migration in response to release media from days 20-22.  
Although SDF-1α-loaded NPs were able to increase nuclei count significantly relative to 
blank NPs, the difference was not statistically significant in comparison to the negative 
control. (* & ** represents p<0.05 and p<0.001 respectively, relative to negative control 
and $ represents p<0.05 relative to blank NPs). 
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Figure 3.4: Specific protein-protein interactions exist between SDF-1α and fibrin(ogen). 
(A) Schematic depicting fibrinogen binding assay that consisted of high-binding ELISA 
plates coated with the soluble factors, bovine serum albumin (BSA; negative control), 
FGF (positive control) and SDF-1α ELISA setup used to measure fibrinogen binding 
affinity. (B) Signal from SDF-1α coated wells were significantly higher compared to 
negative controls (BSA) and comparable to the positive control (FGF) suggesting a 
specific interaction between SDF-1α and fibrinogen. (C) Increase in signal from 
fibrinogen binding is attenuated for FGF and SDF-1α-coated wells in a dose-dependent 
manner due to competition from soluble heparin. In contrast, BSA-coated wells do not 
exhibit heparin-dependant change in signal. (D) ELISA designed to probe fibrin 
interactions with SDF-1α where high-binding ELISA plates were coated with a thin layer 
of fibrin, BSA (negative control), and heparin (positive control).  (E) A concentration-
dependent increase in signal was observed for the fibrin-coated wells, similar to the 
trend observed for the positive control suggesting SDF-1α interactions persist in the 
polymerized form of fibrinogen, fibrin. (** represents p<0.001 relative to negative BSA 
control). 
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Figure 3.5: SDF-1α sequestered in fibrin matrices. (A) Release profile of free SDF-1α was 
significantly altered by encapsulation in different densities of fibrin. The 25mg/ml group 
showed a release of 20% after 2days, with no detectable SDF-1α released up to day 7. In 
contrast, the 3mg/ml released 90% of its cargo within the first 2days. (B) To ensure that 
the differences seen in the release profile were not due to problems with SDF-1α 
detection, the fibrin matrices were digested using plasmin and the total protein detected 
was similar to the initial payload for both groups.  
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Figure 3.6: Magnitude of burst release from SDF-1α-loaded NPs was modulated with 
fibrin. (A) SDF-1α release from first three days was significantly modulated by 
embedding NPs in different concentrations of fibrin. After 24hrs, the 25mg/ml group 
was able to reduce SDF-1α detected in the release media by 60% relative to free NPs. B) 
Total SDF-1α detected was significantly different between the free NPs and 10mg/ml, as 
well as the 10 and 25mg/ml groups. Although the total SDF-1α detected after 72hrs in 
the 3mg/ml group was not significantly different, at 24hrs cumulative SDF-1α is 
decreased by 25% in the fibrin group. (* represents p<0.05 relative to free NPs; $ 
represents p<0.05 relative to 25mg/ml fibrin group). 
 
Figure 3.7: NP encapsulation does not significantly affect fibrin clot properties. (A) 
Percent clottable protein is not a function of NP encapsulation (up to 10mg/mL). 
Presence of NPs do not affect the ability of fibrinogen to interact with other monomers to 
form the insoluble fibrin clot. (B) Terminal turbidity of fibrin clots is not affected by NP 
concentrations up to 10 mg/mL. The increase in turbidity seen in the 3mg/mL 
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fibrinogen group with 10mg/mL NPs is likely due to the presence of the NPs themselves. 
(C) Storage (G’) and loss (G”; dotted plots) moduli of 3mg/mL (green) and 30mg/mL 
(red) fibrin clots. Native fibrin (no NPs) and fibrin with 10mg/mL NP illustrate that the 
presence of NPs cause minimal changes in fibrin mechanical properties. (D) Overall 
strength of 3mg/mL fibrin gels are not a function of NP content. Although 30mg/mL 
gels did show significant differences at 1 & 10mg/mL NP groups, two-way ANOVA 
analysis indicates NPs do not play a statistically significant role in fibrin storage modulus 
(p=0.05). (* represent p<0.05 relative to 30mg/mL fibrin with 0mg/mL NPs). 
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CHAPTER 4 
SPATIOTEMPORAL PRESENTATION OF EXOGENOUS SDF-1 MODUATES THE IN-
VIVO OF SDF-1/CXCR4 SIGNALING AXIS IN THE RODENT CORTEX 
4.1. Introduction 
 The SDF-1α/CXCR4 signaling axis has gained considerable attention as a 
therapeutic target in diverse areas of study such as immune-modulation, trafficking of 
stem cells and cancer metastasis.  Among them is the role of SDF-1α in the migration of 
neural progenitor/stem cells (NPSCs) during pathological conditions of the central 
nervous system (CNS) [255], [256]. After neural injury (traumatic brain injury, TBI, or 
stroke), NPSCs in the neurogenic niches, exhibit a remarkable ability for directed 
migration to reach the injury penumbra [36], [81]. Migrated NPSCs not only maintain 
neurogenic capacity, but they also secrete neurotropic factors and assist in preserving 
synaptic connectivity in the injury area [255], [257]. As such, ablation of endogenous 
NPSC populations before induction of neural injury significantly hampers the 
endogenous neurogenic potential contribution to increased cognitive impairments [83]. 
However, this NPSC migratory response is transient, peaking at 3-7 days post injury (in 
rodent models) and decreases dramatically, although not completely, by two weeks post 
injury [87]. Mechanisms controlling this endogenous injury response are not yet fully 
understood, but the SDF-1α/CXCR4 signaling cascade is thought to play an important 
role due to the following: 1) NPSCs are CXCR4+ and respond chemotactically to SDF-1α 
gradients in vitro [4], 2) NPSCs migrate to local sources of SDF-1α in vivo after neural 
injury [36], [81], 3) local administration of the CXCR4 antagonist, AMD3100 attenuates 
NPSC migration [84], and 4) decreasing local concentrations of SDF-1α coincides with 
the aforementioned decrease in the number of migrating NPSCs in vivo after neural 
injury [81], [87]. Thus, control over the local bioavailability of SDF-1α serves as a 
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potential means for amplifying/sustaining the innate NPSC homing response after 
neural injury. We have previously developed poly(D,L,-lactic-co-glycolic) acid (PLGA) 
nanoparticles (NPs) that encapsulate and release bioactive SDF-1α over a period of 60 
days [258].  PLGA is FDA-approved and PLGA-based NPs have the added benefits of: 1) 
direct injection into target tissues, 2) biodegradability, 4) metabolizable degradation 
products and, 5) lowering risks of infections compared to conventional osmotic pumps 
[222], [258]. Moreover, PLGA matrices maintain prolonged, localized bioavailability and 
may aid in protecting the encapsulated cargo from degradation, a critical parameter for 
protein delivery [187], [191], [192].  
 Growing evidence indicates that the spatio-temporal presentation of bioactive 
factor(s) alters the overall biochemical cellular response. For example, sustained release 
of proteins differentially affects stem cell proliferation, migration and differentiation 
both in vitro and in vivo when compared to bolus administration [140], [141], [259]. 
Additional studies demonstrate that sustained release of proteins do not always lead to 
an improvement in therapeutic efficacy [142], [146]. Instead, differing protein release 
profiles (bolus, sustained, delayed and pulsed) may activate distinct biochemical 
cascades that determines overall therapeutic outcome [260]. Additionally, receptor 
desensitization/downregulation due to overstimulation is another well-known 
phenomenon that may occur with sustained controlled release devices [144], [145].  
Specifically, for SDF-1α/CXCR4, it is unclear how or if autocrine/paracrine signaling 
affects regulation of SDF-1α/CXCR4 expression. Furthermore, discovery of a second 
SDF-1α receptor, CXCR7, further complicates our understanding of how the SDF-1α 
mediated signal transduction propagates. Some in vitro evidence points to 
downregulation of CXCR4 after continuous exposure to SDF-1α in neonatal E14.5 
telencephalic neurons, but its relation to native cortical tissues in the mature forebrain 
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where multiple cell-types express CXCR4 and secrete SDF-1α is not certain [15], [186]. 
Although a number of studies have focused on endogenous SDF-1α/CXCR4 signaling in 
the developing brain and after neural injury, none have directly assessed endogenous 
SDF-1α/CXCR4 signaling in response to different spatiotemporal presentations of 
exogenous SDF-1α. We believe that this represents a fundamental barrier in the 
development of efficacious strategies for manipulating the SDF-1α/CXCR4 signaling 
cascade, a ubiquitous therapeutic target for diverse applications.  
 The goal of this study was to begin elucidating the SDF-1α/CXCR4 signal 
propagation in the adult rodent cortex in response to either bolus or sustained release of 
exogenous SDF-1α. To facilitate a more direct correlation between administration of 
exogenous SDF-1α and endogenous SDF-1α/CXCR4 signaling, we performed in vivo 
studies in the intact (uninjured) mouse cortex to avoid confounding factors otherwise 
present in the complex injured microenvironment [255]. Critical tools employed include: 
1) transgenic (CXCR4-EGFP) mice that have a intracellular reporter (enhanced green 
fluorescent protein; EGFP) for CXCR4 expression [186], 2) fluorophore-conjugated SDF-
1 (AFSDF-1) that retains bioactivity and, 3) PLGA nanoparticles that encapsulates 
bioactive AFSDF-1 [258]. Using this toolset, we tracked spatiotemporal localization of 
endogenous SDF-1 and CXCR4+ cells (1, 3 & 7 day timepoints) in response to 
intracortical injections of either bolus AFSDF-1 or AFSDF-1-loaded NPs. We 
hypothesized that endogenous SDF-1/CXCR4 expression will increase acutely after 
exposure to both bolus and controlled release of exogenous AFSDF-1. However, bolus 
administration leads to a transient response from the endogenous SDF-1/CXCR4 
signaling axis; whereas sustained release of exogenous SDF-1α may lead to 
downregulation of CXCR4 expression overtime despite bioavailable exogenous SDF-1. 
The results of these experiments will inform design and testing of future biologically 
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relevant release devices capable to modulating the SDF-1/CXCR4 signaling axis over 
extended periods of time.  
4.2. Experimental Methods 
4.2.1 Materials 
 Poly(lactic-co-glycolic) acid (PLGA; 50:50 ester-terminated; inherent viscosity = 
0.55-0.75dL/g) was purchased from Lactel (Birmingham, USA). Recombinant mouse 
stromal cell-derived factor-1 α (SDF-1α) were acquired from PeproTech (Rocky Hill, 
USA). Recombinant human-derived SDF-1α conjugated with AlexaFluor-647 at the C-
terminus (AFSDF-1) was acquired from Almac (Craigavon, UK). B27 growth supplement, 
DAPI nuclear stain, and Dulbecco's modified eagle medium were acquired from Life 
Technologies (Carlsbad, USA). Glucose was obtained from Acros Organics (Geel, 
Belgium). The organic solvent ethyl acetate was acquired from Alfa Aesar (Ward Hill, 
USA) and dimethyl sulfoxide (DMSO) from American bioanalytical (Natick, USA). All 
other materials and chemicals were purchased from Sigma-Aldrich (St. Louis, USA) and 
used without further modification or purification. 
4.2.1 NPSC Harvest and Culture 
 Murine fetal derived neural progenitor/stem cells (NPSCs) were isolated from the 
medial and lateral germinal eminences of E14.5 C57BL/6 mice based on previously 
published protocols and in accordance with approval by the Institutional Animal Care 
and Use Committee at Arizona State University [235]. The germinal eminences were 
harvested, mechanically disassociated and cultured in NPSC medium (Dulbecco's 
modified eagle medium (DMEM:F12) with 2.4mg/mL sodium bicarbonate (NaHCO3), 
6 mg/mL glucose, 5mM HEPES, 62.9 ng/mL progesterone, 9.6 μg/mL putrescine, 
1.83 μg/mL heparin, 1X B27 growth supplement, 20 ng/mL epidermal growth factor 
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(EGF), 5 ng/mL FGF, 5 μg/mL insulin, 5 μg/mL transferrin, and 5 ng/mL sodium 
selenite). NPSCs were cultured as non-adherent neurospheres and used for 
experimentation between passages 3-6.  
4.2.2 Chemotactic NPSC Migration Assay 
 NPSC chemotaxis in a modified-Boyden chamber assay was used to validate 
AFSDF-1 bioactivity on mouse-derived NPSCs as previously described [12]. In short, 
disassociated NPSCs were plated (70,000 cells/cm2) on laminin-coated transwell inserts 
with 8µm pore diameter (Millipore, Temecula, CA). Growth factor-free NPSC medium 
(no EGF or FGF) with 0, 250, or 1000ng/mL SDF-1α was added in the bottom chamber. 
NPSCs were then allowed to undergo chemotaxis for 24hrs in an incubator (370C and 5% 
CO2). Subsequently, cells on the topside of the transwell membrane were removed using 
a cotton swab whereas migrated cells that reached the bottom were fixed, underwent a 
DAPI nuclear stain and imaged. NPSC nuclei have diameters of approximately 20µm 
[236]. After intensity thresholding, nuclei count was quantified using a particle count 
algorithm in ImageJ where stained nuclei 10-30µm in diameter were counted as 
individual cells. Nuclei count was determined by imaging and quantifying whole 
transwell membranes. 
3.2.2. Fabrication of AFSDF-1 Loaded Nanoparticles 
 AFSDF-1 loaded PLGA nanoparticles were fabricated using a water/oil/water 
(W/O/W) emulsion technique using a previously published protocol [258]. Briefly, the 
first emulsion (W/O) was obtained by vortexing the oil phase (100 mg/mL PLGA in ethyl 
acetate) with PBS buffer solution (pH = 7.4) containing 2.0mg/mL AFSDF-1 (0.2% w/w 
of PLGA). The above solution was added dropwise to a 3.6x volume excess of an aqueous 
5.0% (w/v) d-α tocopheryl polyethylene glycol 1000 succinate (TPGS) and the second 
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emulsion (W/O/W) was produced by ultrasonicating (Omni Ruptor 4000; Omni 
International; Kennesaw, USA) the solution for two consecutive 15sec periods in an ice 
bath. The emulsion was then quickly transferred to a stirring (300RPM) aqueous bath 
containing 0.5% TPGS + 1.25% (w/v) NaCl (10x volume excess) and left undisturbed for 
3hrs for solvent evaporation. The particle suspension was washed three and recovered 
through lyophilization.  
4.2.3 Animal Model 
 The CXCR4-EGFP transgenic mice were kindly donated to us by Dr. Richard 
Miller of Northwestern University. All studies were conducted in accordance with 
approved protocols reviewed by the Institutional Animal Care and Use Committee at 
Arizona State University. The CXCR4-EGFP mice are well characterized and utilized in 
studies characterizing the developing and adult rodent CNS [186], [261], [262]. CXCR4–
EGFP bacterial artificial chromosome (BAC) transgenic mice was originally developed by 
the gene expression nervous system atlas (GENSAT; NINDS contract N01Nso2331 to 
Rockefeller University, NY). Expression of EGFP in these mice is expected to be identical 
to endogenous gene expression as examined by in situ hybridization 
(http://www.gensat.org/index.html).  
4.2.4 Controlled Cortical Impact (CCI) Model of TBI: Validation of Transgenic Mouse 
All studies were conducted in accordance with approved protocols reviewed by 
the Institutional Animal Care and Use Committee at Arizona State University. CCI was 
used to produce unilateral cortical contusions in adult, male and female CXCR4-EGFP 
transgenic mice to validate that the animal model recapitulates known known CXCR4 
and SDF-1 patterns after CCI [263]. Briefly, the mice were anesthetized using isoflurane 
and immobilized in a stereotactic frame (Leica; Wetzlar, Germany). A biopsy punch was 
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used to produce a 3 mm diameter craniotomy centered on 1.5 mm anterior of bregma 
and 1.5 mm lateral of midline leaving the dura mater intact. A 2 mm diameter piston was 
then centered over the craniotomy and was electromagnetically driven 1 mm into the 
cortical tissue at a velocity of 6 m/s for a duration of 200 ms (ImpactOne, Leica). At 
specified timepoints post-injury, the mice were anesthetized and sacrificed through 
pericardial perfusion to extract the brain that was post-fixed in 4% paraformaldehyde for 
24 hrs.  
4.3.5. Intracortical Injections 
 Adult, male and female CXCR4-EGFP transgenic mice (n=5 per group/time 
point) were anesthetized and a 1.5mm craniotomy was performed centered over 1.5mm 
anterior of bregma and 1.5mm lateral of midline. 3μL injections were performed at a 
depth of 0.8mm into the cortical tissue using a 26G needle for the following groups: 1) 
bolus AFSDF-1α, 2) bolus vehicle, 3) AFSDF-1α NPs and, 4) NP vehicle. Separate 
Hamilton syringes and needles were used for all groups (Hamilton, Reno, NV). The 
syringe and needle was stereotaxically placed, lowered 0.8 mm into the cortical tissue at 
a rate of 0.15 mm/min and kept stationary for 1 min. The needle was then retracted back 
up to 0.5 mm before the injections were initiated at 0.5 μL/min, pausing every 1µl for 
30s until 3µl dose was delivered. The needle was subsequently held in place for 1 min 
before being retracted at 0.15 mm/min. For the particle groups, lyophilized NPs were 
resuspended at 140mg/ml, subjected to water-bath sonication (on ice) for 2mins 
immediately before the injection procedure. After the operation, mice were anaesthetized 
and sacrificed at 1, 3, and 7 days post-injection by pericardial perfusion to extract the 
brain that was post-fixed in 4% paraformaldehyde for 24 hrs. 
4.3.6 Immunohistochemistry and Image Processing 
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 Following fixation, extracted brain tissues were saturated with sucrose by 
incubation in 30% sucrose for 48hrs. The specimen was then cryo-fixed and serially 
sectioned at 25µm thickness. Sections were blocked with goat serum, permeabilized and 
stained for SDF-1α (rabbit anti-SDF-1α, Abcam; AlexaFluor-555 conjugated goat anti-
rabbit, Life Technologies). Stained sections were visualized using fluorescence 
microscopy (DMI6000B, Leica) and 20x tiles scans were used to produce cortical 
representations. Fluorescence-based semi-quantitative analysis were conducted on the 
resulting images using ImageJ to determine spatiotemporal localization of CXCR4+ cell 
bodies as well as, endogenous SDF-1α and exogenous AFSDF-1.  
 Some differences in tissue and cellular morphology were observed at the needle 
tract between the bolus and NP implant groups (discussed in the following sections; 
Figure 4.1). Thus, two different approaches were used to assess the effects of bolus 
administration (AFSDF-1 vs vehicle) as well as, differences between bolus and sustained 
release of AFSDF-1. All cortical representations were first divided in four basic zones 
(Figure 4.1):  
1) Needle tract: Region of tissue (100-200 μm across) that was punctured by the needle 
to administer the injections.   
2) Injection site: a 600 μm section centered on the needle tract. 
3) Proximal to injection: two 400 μm sections located directly adjacent to the injection 
site (medially and laterally). 
4) Distal to injection:  Remaining portions of images that extends past 700 μm from 
the needle tract in both, medial and lateral directions out to 1700 μm.  
  Secondly, three regions of interest (ROIs) that make up one or more of the above 
zones were selected based on the type of comparison (Figure 4.1). The principal 
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difference was omitting the injection site for any comparisons that include the sustained 
release groups (Figure 4.1). Thirdly, relative differences in CXCR4+ cell density and 
SDF-1 localization with respect to the needle tract were determined using an average of 
12 cortical representations for every group, at each timepoint. CXCR4+ cells exhibited 
strong EGFP signal where cell bodies with intermediate or weak EGFP expression was 
not prevalent (Figure 4.3B). The apparent “on/off” nature of the endogenous CXCR4 
expression reporter allowed for thresholding, followed by particle count algorithms to 
determine total count and spatio-temporal localization of CXCR4 overexpressing cells. 
SDF-1 immunostains on the other hand, indicated complex, non-uniform patterns of 
staining, especially in the AFSDF-1-loaded NP groups. Additionally, IHC stains are 
considered “semi-quantitative” due to a host of variables related to tissue processing 
before, during and after completion of IHC [264]. Thus we used contralateral-adjusted 
(to minimize subjectivity) thresholding values to determine the area fraction of SDF-1 
overexpression in the desired ROIs. These semi-quantitative measurements are 
presented to glean overarching patterns in SDF-1 localization between the experimental 
groups.  
4.3.7 Statistical Analysis 
 Statistical analysis was performed on all quantitative assays. All results are 
depicted as the mean ± one standard deviation, unless otherwise stated. Statistical 
analyses (GraphPad Prism, La Jolla, CA) evaluated differences between groups using 
analysis of variance (ANOVA) followed by Tukey post-hoc tests to determine statistical 
significance with p < 0.05 considered significant. Multiplicity adjusted p-values are 
reported for Tukey post-hoc comparisons. 
4.3. Results 
4.3.1. Validation of AFSDF-1 and CXCR4-EGFP Mouse Model 
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 The N-terminus of SDF-1 is critical for binding and activation of CXCR4 [265]. 
Thus, site-specific modifications at the C-terminus is predicted to better maintain SDF-1 
bioactivity [266]–[269]. The only commercially available fluorescently-tagged SDF-1 was 
human-derived recombinant SDF-1 with AlexaFluor-647 conjugated to the C-terminus 
(AFSDF-1) from Almac Chemokines (Craigavon, UK). Previous studies have noted cross-
reactivity between diverse species, yet we wanted to verify that mouse NPSCs respond to 
this human AFSDF1. A modified-Boyden chamber migration assay was used with 8μm 
pore width membranes. NPSCs were plated on the topside of membrane and the nuclei 
of cells that migrate to reach the bottom in response to SDF-1α were counted after a 24hr 
incubation period. Since the SDF-1 gene is over 90% homologous between mouse to 
human species, both types of SDF-1α elicited a similar pattern of migratory behavior 
from mouse-derived NPSCs (Figure 4.2) [270]. Three different SDF-1α concentrations 
(0, 250 & 1000ng/ml) were evaluated in the bottom chamber of the Boyden assay. 
Nuclei count increased in a SDF-1α dose-dependent manner although only the human 
SDF-1α at 1000ng/ml elicited a statistically significant change in nuclei count. 
Regardless, similar patterns in NPSC response validated the bioactivity of human-
derived SDF-1α on mouse NPSCs.  
 The CXCR4-EGFP animal model has been characterized in literature extensively 
to study development in prenatal mice as well as pathology in adult mice [38], [262], 
[271], [272]. However, we are the first to our knowledge to utilize them in the context of 
TBI. To demonstrate validity of the CXCR4-EGFP animal as a model for focal injury 
models of TBI, we performed CCI injuries and probed for SDF-1 
(immunohistochemistry; IHC) and CXCR4 (intracellular EGFP) one day-post injury. The 
CXCR4-EGFP transgenic mice recapitulated known SDF-1 and CXCR4 overexpression in 
the pericontusional region acutely in response to CCI (Figure 4.3) [36], [81], [87]. The 
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ipsilateral cortex exhibited high concentrations of EGFP+ cell bodies (indicating CXCR4 
overexpression) relative to contralateral. SDF-1 immunostaining also qualitatively 
revealed relatively strong signal in the ipsilateral cortex.  
4.3.2. AFSDF-1 Delivery and Diffusion in the Cortex 
 Intracortical injections of 420μg of PLGA NPs was expected to release 29.4 ng of 
AFSDF-1 in the first 24hrs and an additional 9.1 ng through the following 7 days as 
estimated from previously published release profile of SDF-1α from PLGA NPs 
fabricated under the same conditions [4]. Previous in vivo studies deliver significantly 
higher doses of SDF-1 (4μg) in the form of bolus injections [168], [218]. We were 
however constrained by the AFSDF-1 loaded PLGA NPs, specifically its protein loading 
capacity and the total deliverable dosage of NPs in the cortex. Thus, AFSDF-1 dosage in 
the bolus group was 30 ng to match the estimated cumulative AFSDF-1 release in the 
first 24hrs from the NPs. One day post-injection, penetration of bolus AFSDF-1 in the 
cortex was limited approximately to 100 μm from the needle tract (Figure 4.4A). For the 
sustained release groups, strong AFSDF-1 signal in the immediate vicinity of the 
injection tract may indicate both released and encapsulated AFSDF-1 (Figure 4.4B). 
Whereas more diffuse and significantly weaker signal near the periphery of the injection 
tract likely indicated diffusion of exogenous AFSDF-1 in the cortical parenchyma (Figure 
4.4C).  Although fluorescent signal from AFSDF-1 does not necessarily indicate its 
bioactivity, the short diffusion lengths agree with previous studies that report limited 
protein diffusion in the brain parenchyma [136], [273], [274].   
4.3.3. Bolus AFSDF-1 Induced Transient and Localized Expression of CXCR4 
 Nuclear staining (4',6-diamidino-2-phenylindole; DAPI) qualitatively indicated 
some disruption in tissue organization in the immediate vicinity (within 50-100 μm) of 
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the needle tract after bolus injections (Figure 4.5). Bolus AFSDF-1 induced increased 
local expression of CXCR4 as indicated by intracellular EGFP signal that colocalized with 
DAPI nuclear stain (Figure 4.5). Here, the majority of CXCR4+ cells along with AFSDF-1 
were localized in close proximity to the needle tract. CXCR4+ cells in and around the 
needle tract exhibited relatively well compartmentalized EGFP signal suggesting intact 
plasma membranes (Figure 4.1B). Across the total ROI evaluated (~2.8 mm; Figure 
4.1A), the CXCR4+ cell body density (# of cells/mm2) 1 day post bolus injection of 
AFSDF-1 significantly increased relative to vehicle. Moreover, this maximal response at 1 
day post injection was significantly higher than bolus or vehicle injections at 3 and 7 days 
post injection (Figure 4.6A). Total CXCR4+ cell density decreased for bolus AFSDF-1 at 
day 3 & 7, where AFSDF-1 bolus was comparable to vehicle injection (Figure 4.6A). No 
significant differences were observed in the vehicle groups across the 1, 3, and 7 days 
post injection (Figure 4.6A). Looking solely at the region proximal to the injection site, 
bolus AFSDF-1 elicited a modest yet significant increase in CXCR4+ cell density 
compared to vehicle at day 1 (Figure 4.6B). This significance was not observed at day 3 
and 7 and CXCR4 expression returned to levels similar to the vehicle group (Figure 
4.6B). Bolus injection of AFSDF-1 had no impact on CXCR4 expression at most distal to 
the injection site (~700um away; Figure 4.6C), suggesting that the vast majority of the 
CXCR4+ cell bodies in response to bolus AFSDF-1 were located at the injection site. 
Results suggest that a 30ng payload of bolus AFSDF-1 has localized and transient effects 
on CXCR4 expression that then decreases between day 3 and 7 post injection.  
4.3.4. Bolus AFSDF-1 Did Not Modulate SDF-1 Expression Outside of the Injection site 
IHC trends for total SDF-1 (endogenous and exogenous) suggested an increase in 
total SDF-1 immunostaining (as measured by % area) at day 1 relative to all vehicle 
groups, but not the day 3 or 7 AFSDF-1 groups (Figure 4.7A). Total SDF-1 
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immunostaining continued to trend downwards until day 7 comparable to the vehicle 
group (Figure 4.7A). AFSDF-1 administration does not affect overall SDF-1 expression at 
either the proximal or distal ROIs (Figure 4.7B & C). As such, increases in total SDF-1 
levels were likely due to changes occurring in the injection site (Figure 4.8). A substantial 
source of total SDF-1 surrounding the needle tract is exogenous AFSDF-1 signal from 
which was expected to attenuate over time. A decreasing trend in total SDF-1 
immunostaining is also observed at the injection site (Figure 4.8A). However, 
representative images of AFSDF-1 and SDF-1 immunostains indicated an incomplete 
overlap between exogenous and total SDF-1 at the needle tract (Figure 4.8B – G). Thus, a 
transient expression of endogenous SDF-1 due to AFSDF-1 administration may 
contribute to the overall increase in SDF-1 immunostaining observed at day 1 for the 
AFSDF-1 bolus group (Figure 4.7A). Furthermore, bolus AFSDF-1 administration did not 
affect endogenous SDF-1 expression in areas proximal and distal to the injection site 
(Figure 4.7B-C). It is also important to note that neither SDF-1 immunostaining, nor 
AFSDF-1 fluorescent signal is a direct measurement of bioactive SDF-1; rather the 
former is representative of an epitope site that mediates binding with the SDF-1 primary 
antibody and the latter, AlexaFluor-647 fluorophore stability.  
4.3.5. Sustained Release of AFSDF-1 Induced Transient CXCR4 Expression in Cells 
Located Distally from the Injection site 
 As mentioned previously, quantifications for the particle groups excluded the 
injection site and thus, total CXCR4 counts were no provided, instead, only the proximal, 
distal and “proximal + distal” ROIs were quantified. Sustained release of AFSDF-1 
elicited a significant increase in CXCR4+ cell density in the “proximal + distal” ROI 
(Figure 4.1C) at day 1 compared to both blank NP and AFSDF-1 bolus groups (Figure 
4.9A). Subsequently, CXCR4+ cell density decreased at day 3 for the AFSDF-1 NPs 
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compared to blank NP yet remained significantly higher than the AFSDF-1 bolus group. 
By day 7, CXCR4+ cell density was comparable between all groups in the proximal + 
distal ROI (Figure 4.9A). Looking more closely at the region proximal to the injection 
site, CXCR4+ cell density was significantly higher at days 1 & 3 for the AFSDF-1 NPs 
compared to their respective bolus AFSDF-1 groups, but not the blank NPs 
(Figure4.10B). No statistically significant trends were observed at day 7. Most distally to 
the injection site, CXCR4+ cell density for AFSDF-1 NP was increased significantly at day 
1 compared to all other groups in the study (Figure 4.9C). However, the number 
CXCR4+ cells decreased at day 3, eventually approaching the control groups by day 7. It 
is also important to note that some replicates for the blank NPs exhibited relatively high 
CXCR4+ cell density outside of the injection site. A significant difference between the 
blank NPs and bolus vehicle group was noted at day 1 (p=0.023) for the proximal ROI, 
however no other time-matched comparisons were statistically significant between the 
two control groups (Figure 4.12). Furthermore, no statistically significant time-matched 
comparisons were found between the Blank NP and Bolus AFSDF-1 group (Figure 4.12).  
4.3.6. Sustained Release of AFSDF-1 Affected SDF-1 Immunostaining Beyond the 
Injection Site 
 SDF-1 immunostaining, especially for the AFSDF-1 NPs resulted in highly 
complex and non-homogenous distribution of positive staining with relatively high 
variability between replicates (Figure 4.10). Additionally, averaging the medial and 
lateral percent area of positive immunostaining (for the proximal and distal ROIs) did 
not account for the non-uniformity of SDF-1 signal distribution. Regardless, the overall 
trends suggest that SDF-1 levels were relatively higher for the AFSDF-1 NP group 
compared all blank NP and bolus AFSDF-1 groups outside of the injection site 
(“proximal + distal” ROI; Figure 4.11A). Focusing on solely the region adjacent to the 
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injection site (proximal ROI), SDF-1 immunostaining was significantly increased with 
AFSDF-1 NPs as compared to blank NPs only at one day post injection (Figure 4.11B). 
However, no statistical difference was revealed in regions most distal to the injection site 
(Figure 4.11C).  
4.4. Discussion 
 The SDF-1/CXCR4 signaling axis is implicated in a host of pathological 
conditions, is thus investigated as a therapeutic target in diverse applications such as 
cancer metastases and tissue engineering after injury [11], [255]. Thus elucidating 
mechanisms that efficiently modulate the SDF-1/CXCR4 signaling axis is of great value. 
Bolus delivery is the most common method used to study the effects of exogenous SDF-1 
thus far in the CNS [168], [218]. Although, bolus injections have inherent advantages 
such as local delivery in the target tissue and control over dosage, it negates temporal 
control over concentration or payload degradation leading to only transient therapeutic 
benefits. Bioengineered approaches for sustained SDF-1 bioavailability include a number 
of hydrogel-based devices for various applications with diffusion-limited release periods 
of 7-14 days [170], [171], [173], [178]. Others have proposed polyester-based systems to 
prolong release over period of weeks to months [180], [185]. We have previously 
developed and characterized PLGA nanoparticles (NPs) that sustains release of bioactive 
SDF-1α over 60 days [258]. However, given the complexity and possible auto-regulatory 
processes that modulate SDF-1α signal transduction, it is unclear whether slow, and 
sustained release of SDF-1α locally is the most efficacious means of modulating the SDF-
1/CXCR4 signaling axis in the long-term. Indeed recent reports suggest downregulation 
of CXCR4 when continuously stimulated with SDF-1 [15]. Others are shedding light on a 
new receptor, CXCR7 that modulates sensitivity to extracellular SDF-1 [20]. There is a 
lack of studies devoted to understanding how the SDF-1/CXCR4 signaling axis responds 
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to various spatiotemporal presentations of exogenous SDF-1 in vivo. We thus used the 
CXCR4-EGFP transgenic mouse model to study the effects of bolus and controlled 
release of exogenous AFSDF-1 on the endogenous spatiotemporal localization of SDF-1 
and CXCR4-expressing cells over a period of 7 days.   
 AFSDF-1 penetration in the cortical tissues was limited, detectable AFSDF-1 
bolus payload was confined to within 100μm from the needle tract (Figure 4.4). Once in 
the interstitial space, protein diffusion, rather than convection is the main mechanism of 
transport in the brain extracellular space (ECS). Diffusion over short distances (<0.1mm) 
is relatively efficient, however the densely packed architecture of the ECS means 
diffusion in the order of millimeters is unlikely to occur in therapeutically-relevant time 
scales [131]. In addition to a small void fraction, cortical extracellular matrix (ECM) is 
composed of negatively charged components such as hyaluronic acid, heparan sulfate 
and chondroitin sulfate proteoglycans among others. Thus, diffusion of highly basic 
proteins such as SDF-1 (isoelectric point ~9.6 for the SDF-1α isoform) is expected to be 
hindered and/or be fully immobilized due to electrostatic interactions. Since 
encapsulated and released AFSDF-1 could not be differentiated near the needle tract for 
the NP implant groups, comparisons for AFSDF-1 tissue penetration between the bolus 
and sustained release were not presented (Figure 4.4). However, previous studies 
indicate that protein penetration in the brain interstitial space is enhanced through 
sustained release devices (protein release from hydrogels) or continuous infusions (i.e. 
convection enhanced delivery via osmotic pumps) [140], [275]. Enhanced diffusion is 
these cases is partly mediated by a maintenance of a concentration gradient for a longer 
period of time relative to a bolus administration.   
 SDF-1α PLGA NPs were adapted to achieve sustained release of exogenous 
AFSDF-1 [4]. EGFP signal was observed within, and at the edges of the NP implants 
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(Figure 4.10). Previous reports demonstrate PLGA microparticles implants in the 
striatum stimulate localized activation of microglia/macrophage as early as one day post-
injection [276]. Since activated microglia and infiltrating systemic macrophages employ 
the SDF-1/CXCR4 signaling cascade, the EGFP signal from the NP implants is a possible 
indicator of a host response [33], [277]. Further cell phenotype characterizations are 
required to determine if/how immune cell-types contribute to CXCR4+ cell density 
observed near the NP implants. However, the measured outcomes of the study (CXCR4+ 
cell density and SDF-1 immunostains) from blank NP implant groups suggest that the 
NP implants did not induce a widespread foreign body immune response (material 
response; Figure 4.12). Increased CXCR4+ cell density was limited primarily to the 
injection site and increased SDF-1 immunostaining was not observed for any of the blank 
NP groups regardless of timepoint (Figure 4.10 & 4.12). Thus the localized effects of NP 
implants at the injection site were omitted and quantitative analyses comparing the 
effects of bolus and sustained release of AFSDF-1 included the proximal, distal, and 
“proximal + distal” ROIs.  
 We report statistically significant differences in CXCR4+ cellular activity in 
response to a bolus dosage of 30ng of AFSDF-1 [218]. At day 1, 193.1 ± 136 cell 
bodies/mm2 expressed CXCR4 at the injection site, which decreased 12-fold at day 3, 
eventually reaching comparable levels to controls by day 7. This trend may be attributed 
to a decrease in bioactivity/bioavailability of AFSDF-1 over time, especially at the 3 and 7 
day time points. Densely populated EGFP+ cell bodies were closely associated with the 
needle tract at day 1 post bolus injection suggesting that exogenous AFSDF-1 induced 
CXCR4 expression, agreeing with in vitro and in vivo trends reported in literature 
(Figure 4.5) [15], [218], [278]. A wide range of cell types, are expected to contribute to 
the overall CXCR4+ cell densities reported.  CNS resident cell types such as, mature 
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neurons, oligodendrocytes, astrocytes, endothelial cells are not only CXCR4+, but they 
also regulate CXCR4 expression when exposed to SDF-1 [14], [15], [277], [279], [280]. 
Furthermore, NPSCs are CXCR4+ and are known to migrate towards SDF-1 gradients in 
vitro and in vivo [4], [36], [81]. Hematopoietic [281] and mesenchymal stem cells [282] 
from the systemic circulation also home towards local sources of SDF-1. As a result, 
stem/progenitor cells associated with repair and regeneration likely comprised the 
CXCR4+ cell counts in addition to neuronal, glial and immunomodulatory cells. Further 
phenotypic characterization is required to probe which cell types respond to exogenous 
SDF-1.  
Sustained release of AFSDF-1 induced significantly higher total populations of 
CXCR4+ cells compared to bolus AFSDF-1. More importantly, large fractions of these 
CXCR4+ cells were located well beyond the injection site (>300μm from the needle 
tract). For example, the AFSDF-1 sustained release at day 1 was the only group that 
elicited a significant increase in CXCR4+ cell density in the distal ROI (>700um away 
from the needle tract; Figure 4.9C). This observation raises the question of how 
exogenous SDF-1 with minimal direct diffusion into the brain interstitial space (Figure 
4.4) affected cellular activation at such large distances. Previous studies with 
pretreatment of mesenchymal stem cells (MSCs) with SDF-1, upregulated SDF-1 mRNA 
[278]. Thus, the relatively slow release of AFSDF-1 in the sustained release groups (even 
in the first 24hrs) may have induced upregulation of endogenous SDF-1, propagating the 
signal much further than AFSDF-1 can physically diffuse. Additionally, in contrast to 
bolus injection where the entire delivered dose is bioavailable immediately and subject to 
proteolytic degradation, the sustained release group is expected to release AFSDF-1 in a 
more controlled fashion even in the first 24hrs. This slower rate of protein release from 
the NPs may have provided insulation of released AFSDF-1 from environmental factors. 
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Thus, increased CXCR4+ cell density may also be a product of improved AFSDF-1 half-
life and bioavailability [187].  
 Aside from a strict feed-forward autocrine/paracrine signaling loop for SDF-1, we 
cannot rule out the involvement of other propagating signal mediators. Several soluble 
factors  (i.e., vascular endothelial growth factor, VEGF; basic fibroblast growth factor, 
FGF; immune modulators) are known to cross-talk with SDF-1/CXCR4 signaling axis 
[278], [283]. The VEGF interaction with the SDF-1/CXCR4 signaling is of particular 
interest since SDF-1 treatment of MSCs stimulate increased VEGF secretion in vitro 
[278], while other studies indicate that VEGF upregulates expression of both SDF-1 and 
CXCR4 [284]. VEGF and SDF-1 also contain significant overlap in their gene regulation 
(i.e. through hypoxia inducible factor-1), as such endothelial progenitor cells are found to 
express both simultaneously under hypoxia [285], [286]. FGF is another signaling 
mediator that may be involved in transducing AFSDF-1 signal distally. CXCR4 and SDF-1 
expression increases significantly in CXCR4+ endothelial cells after exposure to FGF 
[287], [288]. More interestingly, VEGF and FGF both appear to increase only CXCR4 
expression and do not modulate expression of other CXC or CC chemokine receptors 
[289]. This result suggests that SDF-1, VEGF and FGF take part in a positive feedback 
loop to directly and indirectly propagate SDF-1/CXCR4 signaling [289]. Immune 
modulators such as, tumor necrosis factor-α (TNF-α) and interleukin 1-β (IL-1β) also 
affect the SDF-1/CXCR4 signaling axis indirectly by inducing release of VEGF and/or 
FGF [288], [290]. TNF-α also has a reported biphasic effect on CXCR4 expression 
where, CXCR4 expression is downregulated initially (within in 3 hrs), and upregulated 
subsequently (after 24 hrs) [288], [290]. In this case, TNF-α-mediated expression of 
VEGF and FGF does not fully account for the delayed CXCR4 upregulation, suggesting 
TNF-α plays a more indirect role in modulating the SDF-1/CXCR4 signaling axis [289]. 
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The same biphasic response on CXCR4 expression is observed for interleukin 1-β [290]. 
Other cytokines such as, interferon-γ (IFN-γ) and granulocyte colony-stimulating factor 
(GCSF) are inhibitors of the SDF-1/CXCR4 signaling axis by downregulating SDF-1 
and/or CXCR4 expression [288], [290], [292], [293]. Thus, secondary signaling 
mediators may play an important role in propagating SDF-1/CXCR4 signaling to the 
distal areas of the cortex.  Another mechanism for activation of distal cells may be due to 
exogenous SDF-1 bypassing diffusion through the brain interstitium by entering the 
brain vasculature that may be transiently leaky (i.e. after neural injury, invasive surgical 
procedure to implant NPs). Although it is not empirically apparent that intracortical 
injections lead to breakage of the BBB, neural injuries such as focal TBI are well known 
to cause BBB dysfunction [65]. In the study presented here, escape of AFSDF-1 into the 
systemic circulation through leaky vasculature may allow for alternate means of 
transport and interaction with endothelial cells of the BBB in distal regions of the brain. 
Endothelial cells strongly express both SDF-1 and CXCR4 and as mentioned before, may 
relay signals that directly or indirectly affect endogenous SDF-1 expression in distal 
portions of the brain [287]–[291].  
Although, controlled release of AFSDF-1 showed significantly more diffuse effects 
spatially, these effects were transient, where total CXCR4+ cell density attenuates to 
reach levels comparable to controls by day 7, similar to the bolus injection groups 
(Figure 4.9A). In the distal ROI, the decrease in CXCR4+ cell density occurs by day 3 
(Figure 4.9C). The estimated drop in AFSDF-1 release rate from NPs past the first 24hrs 
may contribute to the eventual return of CXCR4+ cell density to that of control groups by 
day 7. Another potential mechanism may be autoregulation of the SDF-1/CXCR4 
signaling axis. CXCR4 receptor downregulation as well as, CXCR7-mediated SDF-1 
scavenging are known to be a part of the SDF-1/CXCR4 signaling axis [15], [24]. 
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Specifically, when overstimulated with SDF-1, migrating interneurons in the rostral 
migratory stream downregulate CXCR4 and CXCR7 functions as a means of preserving 
adequate CXCR4 concentrations in the plasma membranes [15]. In fact the majority of 
migrating interneurons express both CXCR4 and CXCR7, and selectively interrupting the 
function of either receptor leads to morphological defects in vivo [19]. Figure 4.10E 
depicts a replicate for the day 7 AFSDF-1 NP group where cortical representations 
suggested robust SDF-1 immunostains both lateral and medial to the injection tract. 
However, little to no CXCR4 overexpressing cells were colocalized within the regions of 
positive stains. In comparison, day 1 after bolus injection of AFSDF-1, CXCR4+ cells 
were observed in large numbers colocalized with AFSDF-1 at the needle tract. Similarly, 
sustained release of AFSDF-1 initially elicited increased expression of both SDF-1 (% 
area immunostain) and CXCR4 (cell density). However, CXCR4+ cell numbers 
attenuated by day 7, even for replicates that exhibited strong SDF-1 staining through the 
cortical tissue (Figure 4.10E). This result may indicate CXCR4 downregulation, or 
CXCR-7-mediated SDF-1 desensitization at the later timepoints. Further in vitro studies 
will help determine how SDF-1, CXCR4 & CXCR7 expression relates to sustained 
exposure to SDF-1. Additionally, if desensitization of SDF-1 plays an important role due 
to a sustained release, it remains to be seen whether other release profiles (delayed or 
pulsed) is a better fit for modulating the SDF-1/CXCR4 signaling axis in the week-long 
period tested here, and beyond.  
5.5. Conclusion 
 Bolus administration of exogenous SDF-1 (AFSDF-1) in the intact mouse cortex 
led to localized and transient expression of CXCR4 at day 1, which attenuated completely 
at some point between days 3 and 7 days post injection. SDF-1 immunostain denoting 
total SDF-1 (exogenous + endogenous) increased significantly locally at the injection site. 
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However, we did not tease out the levels of endogenously expressed SDF-1 to specifically 
correlate increased bolus injection of exogenous SDF-1 with increased endogenous 
expression/secretion of SDF-1. Our data conclusively suggested that AFSDF-1 bolus 
injections did not stimulate endogenous SDF-1 expression at the proximal and distal 
ROIs. Sustained release of AFSDF-1 led to significant increases in CXCR4+ cell densities 
locally, and in regions far more distal to the injection site compared to the bolus group. 
However, CXCR4 expression decreased significantly by day 3, and was comparable to 
control groups by day 7. AFSDF-1 sustained release elicited complex patterns of 
widespread SDF-1 immunostains that persisted through day 7 post injections. However, 
high levels of SDF-1 immunostains did not translate to increased CXCR4 expression in 
those areas at the later timepoints. It is not clear whether or not autoregulation of the 
SDF-1/CXCR4 signaling axis played a role in attenuating the effects of AFSDF-1 
sustained release. Further studies are required determine the role of CXCR7 as well as 
how more complex release profiles may be better apt at modulating the SDF-1/CXCR4 
signaling axis over extended periods of time.  
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5.6. Figures 
 
Figure 4.1: Representative fluorescent images of cortical tissue sections and the regions 
of interest (ROIs) used to quantify fluorescent signals. (A) Cortical reconstruction 
centered at the injection tract after a bolus injection of AFSDF-1 and (B) AFSDF-1 loaded 
PLGA NPs. All tissue sections were immunostained for SDF-1 (red channel) and nuclear 
material (DAPI; blue channel). AFSDF-1 is represented in magenta, whereas the 
endogenous CXCR4 expression marker is depicted in the green channel. SDF-1 and 
AFSDF-1 signal exhibited a diffuse pattern, whereas signal from the CXCR4 expression 
marker was confined intracellularly. All cortical reconstructions (2.8mmx1mm) were 
divided into a 600µm injection site, two 400µm sections proximal to injection site, and 
two more 700µm sections distal to the injections site. The figure depicts truncated 
regions of the distal ROI for illustration purposes and extend further medially and 
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laterally as represented by the dashed arrows. Data gathered from the medial and lateral 
sections were averaged before being reported for the proximal and distal ROIs, 
respectively. (B) & (D) are magnified representations of the needle tract outlined in white 
for bolus and NP implant groups, respectively. A high concentration of CXCR4+ cell 
bodies were found inside the needle tract of NP groups compared to the bolus groups. 
Scale bars = 100µm for A & C; scale bar = 50um for B & D. 
 
Figure 4.2: Boyden chamber migration assay verified bioactivity of human-derived SDF-
1α on mouse NPSCs. Human SDF-1α was compared to mouse SDF-1α at 0, 250 and 
1000ng/ml. Only the human SDF-1α at 1000ng/ml was statistically different compared 
to control. However, both human and mouse SDF-1α exhibited similar trends in eliciting 
a migratory response from mouse NPSCs. (* represents p < 0.05) 
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Figure 4.3: CXCR4-EGFP transgenic mouse model overexpresses SDF-1 and CXCR4 
after 1 day post injury in a CCI model of TBI. The ipsilateral cortex (A) and a magnified 
region outlined by while dashed line (B) indicates a high density of CXCR4 expressing 
cells (green channel) localized at the cortex. The contralateral cortex (C) and a magnified 
region outlined by while dashed line (D) had little to no cell EGFP+ cell bodies. SDF-1 
immunostaining (red channel) suggests stronger SDF-1 signal in the injured cortex 
(white arrow) relative to a weaker overall signal for the contralateral side.  Scale bars = 
500µm for B & C; scale bar = 100um for D & E.  
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Figure 4.4: Localization of AFSDF-1 signal for all groups is limited to the injection site. 
(A) Distribution of AFSDF-1 one day after bolus injection suggests <100 µm diffusion 
into cortical tissues relative to injection tract. (B) Distribution of AFSDF-1 one day after 
NP implantation. Strong signal within the NP implants indicated encapsulated AFSDF-1. 
(C) Diffuse signal at the edges of the implant indicated AFSDF-1 release and diffusion the 
cortical parenchyma. Evidence of AFSDF-1 penetration into the cortical tissue was 
highlighted (red channel) by thresholding for the highest intensity signals from within 
the implant, as well as the lowest intensity signals to remove background. Scale bars = 
100µm. 
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Figure 4.5: CXCR4 expressing cells colocalize with AFSDF-1 one day after bolus 
administration. (A) Representative fluorescent image centered on the needle tract 
indicating CXCR+ cell density correlates with AFSDF-1 signal. (B) Vehicle injections 
qualitatively a lower number of have CXCR4+ cells around the needle tract. Scale bars 
represent 100µm. Blue = DAPI; magenta = AFSDF-1; red = SDF-1 immunostain; and 
green = CXCR4+ cells. 
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Figure 4.6: Bolus administration of AFSDF-1 has localized and transient effects on 
CXCR4 expression. (A) Total (injection site + proximal + distal) CXCR4+ cell density 
increases significantly at day 1 in response to AFSDF-1, which decreases significantly at 
day 3 and further attenuates becoming comparable to vehicle control by day 7. (B) 
looking only at the proximal ROI, a statistical significance was observed at the day 1 
timepoint, however groups in the day 3 & 7 timepoints were not significantly different. 
(C) No statistical significance was found in the distal ROI. (** represents p < 0.001 
compared to AFSDF-1 at day 1) 
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Figure 4.7: Bolus AFSDF-1 did not modulate ADF-1 expression outside of the needle 
tract. (A) A significant difference in total (injection site + proximal + distal) SDF-1 
immunostaining (% area; normalized to the area of the ROI) was observed for the bolus 
injection group compared to vehicle at day 1 post injection. No other statistically 
significant comparisons were observed for days 3 & 7. (B - C) No statistically significant 
trends were existed for the proximal or distal ROIs. (* represents p < 0.05 compared to 
AFSDF-1) 
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Figure 4.8: Lack of complete overlap between AFSDF-1 signal and SDF-1 immunostain 
may indicate presence of endogenous SDF-1 at the needle tract. (A) Total (endogenous + 
exogenous) SDF-1 at the injection site decreased steadily until day 7 when SDF-1 
immunostaining was comparable with vehicle groups. Representative images of SDF-1 
immunostains (B-D) and AFSDF-1 signal (E-F) at the needle tract indicate lack of 
complete colocalization between the two. Scale bars represent 100 µm. 
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Figure 4.9: Sustained release of AFSDF-1 induced transient CXCR4 overexpression in 
cells located distally from the injection site. (A) CXCR4+ cell density in the proximal + 
distal ROI indicated a significant increase for the AFSDF-1 NP group at day 1 (against 
blank NPs and bolus AFSDF-1) as well as, at day 3 (against only bolus AFSDF-1). (B) 
Focusing only on the proximal ROI, significant differences were found at day 1 & 3 
between the AFSDF-1 NP and bolus AFSDF-1 groups. (C) At the distal ROI, a significant 
difference was seen at day 1 between both, blank NP and bolus AFSDF-1 groups. (** 
represents p < 0.001 compared to AFSDF NPs at day 1; # represents p < 0.05 compared 
to AFSDF NPs at day 3) 
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Figure 4.10: SDF-1 immunostaining for the AFSDF-1 NPs resulted in highly complex and 
non-homogenous distribution of positive staining. (A-B) Cortical representations 
centered around the blank NP implants. As expected, the blank implants do not have any 
AFSDF-1. Moreover, there was not a significant increase in SDF-1 immunostaining 
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regardless of location. Cortical representations of cortices implanted with AFSDF-1 NPs 
at day 1 (C), day 3 (D) and at day 7 (E) with significantly altered SDF-1 immunostaining 
compared to blank NPs. Additionally, some replicates had extensive, non-uniform SDF-1 
staining but did not correlate with the presence of CXCR4+ cells (E). Scale bars 
represent 100 µm. Blue = DAPI; magenta = AFSDF-1; red = SDF-1 immunostain; and 
green = CXCR4+ cells. 
 
Figure 4.11: Sustained release of AFSDF-1 affected SDF-1 immunostaining beyond the 
injection site. (A) SDF-1 staining (% area) in the proximal + distal ROI increased 
significantly at day one for the AFSDF-1 NP group compared to both the blank NPs and 
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bolus AFSDF-1. Although statistical significance against the Blank NPs and AFSDF-1 
bolus did not extend out to days 3 & 7, SDF-1 immunostaining also did not decrease 
significantly over time for the AFSDF-1 NPs. (B) Looking at only the proximal ROI, a 
statistical difference was observed between the AFSDF-1 NP and blank NPs at day 1. No 
other comparisons were significant. (C) No statistical differences were found at the distal 
ROI. (* represents p < 0.05 compared to AFSDF NPs at day 1) 
 
Figure 4.12: Injection of blank or AFSDF-1 NPs did not induce a prolonged and 
widespread material effect. (A) The implantation of blank NPs caused a transient 
increase in CXCr4+ cell density at the proximal ROI relative to bolus vehicle at day 1, 
which decreased by day 7. (B) Implantation of blank NPs had no effect on SDF-1 
immunostaining at the proximal (shown) or any other ROI. (* represents p < 0.05 
compared to Blank NPs at day 1)   
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CHAPTER 5 
SUMMARY AND FUTURE WORK 
5.1. Summary of Findings 
5.1.1. Aim 1: Validate platform for controlled release of proteins with tunable release 
profiles. 
 Due to number and complexity of parameters that affect poly(lactic-co-glycolic) 
acid (PLGA) particle release properties, changing fabrication procedures to achieve a 
desired release profile is both time and labor intensive. We have determined that critical 
release characteristics such as encapsulation efficiency, magnitude of burst release, 
protein release rate and protein release period is correlated to the average diameter of 
the protein-loaded PLGA nanoparticles (NPs) particle populations. Additionally, we 
described how simple centrifugal fractioning parameters may be employed to fractionate 
particles by size, and therefore tune release profiles without having to change the particle 
fabrication parameters, potentially compromising desirable particle attributes. 
5.1.2. Aim 2: Explore composite release systems to modulate sustained release of 
bioactive SDF-1α. 
 PLGA NPs from before to was adapted to encapsulate SDF-1α, which exhibited 
sustained release over a period of 60 days in its bioactive form. The NPs however 
exhibited a high burst release of 23% in the first 24hrs and we explored composite 
systems (NPs in hydrogel) that was hypothesized to potentially sequester burst release. 
We found that SDF-1α has specific binding affinity for fibrin(ogen) and the burst release 
from PLGA NPs can be sequestered in fibrin gels, in a fibrin concentration-dependent 
fashion. Additionally, embedding PLGA NPs in fibrin does not affect fibrin matrix 
properties. These results are significant in potentially obtaining tunable, local and 
115 
 
sustained release of SDF-1α in a variety of applications to modulate the SDF-1/CXCR4 
signaling cascade.    
5.1.3. Aim 3: Determine spatiotemporal expression of endogenous SDF-1a/CXCR4 after 
administration of exogenous SDF-1α in the intact mouse cortex. 
 We contrasted the effects of bolus and sustained release of SDF-1 to determine 
how the endogenous SDF-1/CXCR4 signaling axis responds to spatiotemporal 
presentations of exogenous SDF-1. Bolus administration of SDF-1 leads to localized and 
transient effects of CXCR4 expression and hold a limited capacity to modulate 
endogenous SDF-1 expression. Sustained release of SDF-1 on the other hand, produced 
robust increases in CXCR4 expression even in regions distal to the injection site. SDF-1 
expression was also elevated across the ipsilateral cortex. However, CXCr4 expression 
decreased significantly past day 3. Although the effect of SDF-1 sustained release was 
much more spatially diffuse, it was nearly as transient as bolus injections.   
5.2. Discussion 
 In summary, our overarching goal was to develop platforms to achieve tunable, 
controlled release of SDF-1. FDA-approved polyesters such as PLGA is very common in 
the field of drug delivery due to a number of reasons: 1) they can encapsulate a wide 
range of hydrophobic and hydrophilic molecules, 2) their release profiles can be tuned, 
3) PLGA devices can be injected directly into target tissues, and 4) they have easily 
metabolizable degradation products [258]. Moreover, PLGA matrices maintain 
prolonged, localized bioavailability relative to hydrogels that have relatively short, 
diffusion-limited release kinetics. Once encapsulated, PLGA particles aid in protecting 
the cargo from degradation, a critical parameter for protein delivery (albeit the 
encapsulation process can initially reduce its bioactivity) [187], [191], [192]. However, 
due to the number of interactions involved in determining release profiles from PLGA 
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particle, changing formulation parameters to tune release characteristics can often be 
time and labor intensive. We described a simple centrifugal fractioning method and 
demonstrated a direct relationship between release properties and the particle 
population size characteristics (distribution and average diameter). Encapsulation 
efficiency and several parameters of the release curve (burst release, protein release rate 
and protein release period) were correlated to the average diameter of the particle 
population.  
 Subsequently, we demonstrated successful encapsulation of SDF-1α within PLGA 
NPs and achieve controlled release of bioactive protein over 60days. Functional 
bioactivity of encapsulated and released SDF-1α was demonstrated through in vitro 
NPSC chemotactic migration assays. We also determined that soluble SDF-1α was 
sequestered in fibrin clots and that NPs embedded in different concentrations of fibrin 
was a means for controlling the magnitude of the burst release. These results are 
significant in potentially obtaining tunable sustained release of SDF-1α in a variety of 
injury models, such as after TBI to amplify and/or sustain NPSC-mediated endogenous 
repair response.    
 Thirdly, we contrasted the effects of bolus and sustained release of SDF-1 in the 
intact mouse brain to elucidate underlying mechanisms that would better enable long-
term modulation of the endogenous SDF-1/CXCR4 signaling axis. Bolus administration 
of exogenous SDF-1 (AFSDF-1) in the intact mouse cortex led to localized and transient 
expression of CXCR4 at day 1, which returned back levels comparable to controls around 
3 days post injection. Upregulation of CXCR4 in response to SDF-1 has been reported in 
literature both in vitro and in vivo by multiple cell types [15], [218], [278]. Since cell 
phenotype were not assessed in this study, it is unclear whether higher density of 
CXCR4+ cells were local neurons and/or astrocyte rather than microglia or systemic 
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immune cells that may have chemotactically migrated to local high concentrations of 
AFSDF-1. Moreover, due to the limited diffusivity and short half-life expected from 
AFSDF-1, the increase in CXCR4+ cell density was transient and localized only in the 
injection site. Effect of bolus AFSDF-1 on endogenous SDF-1 expression was 
inconclusive. However, comparisons between SDF-1 immunostains and AFSDF-1 signal 
at the injection site qualitatively supports trends in previous studies that show exposure 
to SDF-1 may directly and indirectly lead to upregulation of SDF-1 [15], [284], [289], 
[290]. No alterations were observed in SDF-1 immunostains in areas proximal and distal 
to the injection site likely due to the limited diffusivity and short-lived effects of bolus 
AFSDF-1.  
Sustained release of AFSDF-1 led to significant increases in CXCR4-
overexpression locally compared to bolus AFSDF-1 and blank NPs. More interestingly, 
sustained release of AFSDF-1 was the only group to significantly increase CXCR4 
expression in cells located distally (>700µm away from the needle tract). This was 
despite the fact that AFSDF-1 was not detected via IHC more the ~200µm away from the 
needle tract. This discrepancy in limited tissue penetration and widespread induction of 
CXCR4+ cells is a strong indicator for secondary and tertiary signaling mediators that 
transduce SDF-1/CXCR4 signaling. VEGF and FGF are both directly involved with the 
SDF-1/CXCR4 signaling axis and are strong candidates for transducing SDF-1-mediated 
signaling beyond the diffusive range of AFSDF-1 in the cortex through 
autocrine/paracrine signaling [289]. In addition, other factors such as TNF-α act 
indirectly to modulate the SDF-1/CXCR4 signaling axis may also have been involved in 
AFSDF-1 mediated signal propagation especially near the NP implants where relatively 
high concentration of activated microglia was expected to be present [276], [291]. There 
is also an outside possibility of NP implants inducing a leaky blood-brain-barrier (BBB) 
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causing AFSDF-1 to reach the systemic circulation undergoing transport through 
convection to reach distal areas of the brain, rather than simple diffusion. AFSDF-1 
interaction with endothelial cells of the BBB may be one direct/indirect mechanism for 
CXCR4+ cells observed far beyond the injection site [287]–[291]. 
Similar to the bolus administration, however, CXCR4-expression for sustained 
release groups decreased significantly by day 3, and was comparable to controls by day 7. 
Thus the effects of sustained release, although much more spatially diffuse, remained 
transient similar to the bolus injection groups. One possible reason for the transient 
response is a significant decrease in the expected rate of AFSDF-1 protein release from 
the NP implants after the first 24hrs. Other potential mechanisms involve auto-
regulatory processes built-in to the SDF-1/CXCR4 signaling axis, namely CXCR7-
mediated AFSDF-1 scavenging/desensitization [15], [24]. In addition to signaling 
mediators that aid in directly and indirectly propagating the SDF-1/CXCR4 signaling 
axis (i.e. vascular endothelial growth factor, VEGF; basic fibroblast growth factor, FGF; 
tumor necrosis factor-α, TNF-α; and interleukin 1-β, IL-1β;) other cytokines such as 
interferon-γ (IFN-γ) act as an inhibitor. IFN-γ treated endothelial cells exhibit a 
significant decrease in CXCR4 expression, and thus sensitivity to SDF-1 [288], [290]. 
Granulocyte colony-stimulating factor (GCSF) is another such factor that has multiple 
effects on the SDF-1/CXCR4 signaling axis. On one hand, GCSF enhances CXCR4 
expression, while on the other, it also induces expression of proteases that rapidly 
degrade SDF-1 [292], [293]. In the bone marrow, GCSF is an important modulator of 
stem cell mobilization through the SDF-1/CXCR4 signaling axis [289]. AFSDF-1 
sustained release also elicited non-uniform and non-symmetric patterns of strong SDF-1 
immunostains that persists through day 7 post injections in some replicates. However, 
higher amounts of SDF-1 at the later timepoints were not correlated to increased 
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CXCR4+ cell density, which was in contrast with the bolus injection group where 
immunostaining for SDF-1 colocalized with CXCR4+ cell bodies near the injection tract 
at day 1. It is not clear whether autoregulation of the SDF-1/CXCR4 signaling axis played 
a role in the apparent decrease in the CXCR4+ cell body count even in the presence of 
SDF-1.  
The injury microenvironment after TBI is significantly more complicated than 
the intact cortex model used in chapter 4. The injury area consists of a diverse profile of 
cells that include resident CNS, as well as systemic stem and immune cell types that 
actively participate in the SDF-1/CXCR4 signaling axis either directly and/or indirectly 
through secondary (e.g. VEGF, FGF etc.) and tertiary mediators (e.g. TNF-α). Moreover, 
the cell phenotypic profile, as well as the resulting signaling milieu is dynamic both 
spatially and temporally making it more difficult to predict how spatiotemporal 
presentation of exogenous SDF-1 may affect the endogenous SDF-1/CXCR4 signaling 
axis. Although, improved bioavailability of exogenous SDF-1 for prolonged periods 
locally after injury is expected to sustain/amplify NPSC-mediated regeneration after 
neural injury, our goal was to control for the complexity of the injury microenvironment 
to study specifically how endogenous SDF-1/CXCR4 signaling axis responds to 
exogenous AFSDF-1. The cumulative data suggests that sustained release of AFSDF-1 
may not be the ideal release profile for modulation of the SDF-1/CXCR4 signaling axis 
over a 7 day period in the intact rodent cortex. More complex release profiles, such as 
delayed and/or pulsed release needs to be evaluated to determine if significant increases 
seen on the first day in the AFSDF-1 sustained release group injections can be repeated 
at various time intervals over an extended period of time.  
5.3. Future Work 
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 To more conclusively substantiate whether sustained release is effective at long-
term modulation of the SDF-1/CXCR4 signaling axis, further studies are required to 
uncover the biochemical basis for the trends observed in the final in vivo study. 
Specifically, future studies will require a wider focus on secondary/tertiary signaling 
mediators that interact with the SDF-1/CXCR4 signaling axis. As mentioned above, 
VEGF and FGF are principal factors that are known to be intimately involved with the 
SDF-1-mediated signaling. Their spatiotemporal localization in addition to SDF-1 will 
provide valuable insights about the underlying biochemical processes that dictate the 
patterns observed. Additionally, tissue sections already acquired from the Chapter 4 in 
vivo study can also be immunostained for CXCR7 where CXCR4+ cells call be compared 
with CXCR7+ cells to gain insights on observed trends. For example, how sustained 
release of AFSDF-1 from NPs resulted in such a significantly different spatiotemporal 
localization of CXCR4+ cell bodies after bolus administration.  
Studying autoregulation of the SDF-1/CXCR4 signaling cascade is another 
important aspect and can be verified using supporting in vitro assays to quantify SDF-1, 
CXCR4 and CXCR7 mRNA expression in response to extended exposure to SDF-1. If 
SDF-1/CXCR4 signaling cascade is desensitized in response to sustained bioavailability 
of SDF-1 in in vitro assays, an interesting question is whether a delayed release profile is 
capable of repeating the trends seen in SDF-1/CXCR4 expression day 1 in the presented 
in vivo study, at later timepoints. If true, a pulsed release profile of SDF-1 is a better 
candidate for long-term modulation of SDF-1/CXCR4 signaling cascade. Better 
understanding of the signaling cascade will lead to development of more biologically 
relevant release devices. To that end, we have already characterized core-shell 
microparticles (MPs) made of both PLGA and poly(L-lactic acid) (PLLA) [294]–[300]. 
Here, a layered structure facilitates delayed release profiles based on cargo localization 
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within the particle [301]. We have developed straightforward protocols that use 
water/oil/oil/water (W/O/O/W) emulsions for encapsulating the model protein, bovine 
serum albumin (BSA) in layered, MPs with PLGA-rich cores and a PLLA-rich shells. We 
also found that ethanol, a polar protic solvent miscible in the water and oil phases of the 
W/O/O/W emulsion, modulated protein localization and particle porosity in layered 
MPs. Moreover, alterations in particle morphology results in distinct release profiles 
where the delay period and subsequent protein release rate is EtOH-dependent. A future 
in vivo study could involve layered MPs encapsulating AFSDF-1 in order to contrast the 
effects of sustained and delayed release. Moreover, combining MPs with different delay 
periods may be means for achieving a pulsed release profiles of SDF-1. 
The injured microenvironment after focal TBI for example, is exceedingly 
complex and dynamic spatially and temporally. In addition to activating the endogenous 
repair response, TBI causes disruptions in CNS (metabolic/ionic) homeostasis, 
breakdown of the BBB, prolonged cell death (necrosis/apoptosis) as well as, 
neuroinflammation. Thus a more nuanced understanding of the mechanisms behind 
SDF-1/CXCR4 signal propagation will better help transition towards evaluating how 
bolus, sustained and delayed/pulsed release of SDF-1 in vivo translates to mobilization 
of endogenous NPSCs in the injured brain.  
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